Patent application title: Therapeutic Compositions for the Treatment of Dry Eye Disease
Inventors:
Reza Dana (Cambridge, MA, US)
Reza Dana (Cambridge, MA, US)
Sunil Chauhan (Somerville, MA, US)
IPC8 Class: AC07K1622FI
USPC Class:
Class name:
Publication date: 2015-09-03
Patent application number: 20150246966
Abstract:
Described herein are materials and methods for treating dry eye disease
in a subject.Claims:
1. A method of treating dry eye disease (DED) in a human comprising:
administering a composition comprising at least one anti-lymphangiogenic
agent and a pharmaceutically acceptable carrier to the eye of the human,
in an amount effective to treat dry eye disease.
2. The method of claim 1, wherein said anti-lymphangiogenic agent is an inhibitor of VEGF-C- or VEGF-D-mediated signal transduction by VEGFR-2 or VEGFR-3.
3. The method of claim 1, wherein the DED is an autoimmune DED or a DED associated with Sjogren's syndrome.
4. The method of claim 1, wherein the DED is DED due to excessively fast tear evaporation (evaporative dry eyes) or inadequate tear production.
5. The method of claim 1, wherein the dry eye disease is attributable to one or more causes selected from: aging, contact lens usage, medication usage,.
6. The method of claim 1, wherein the dry eye disease is a complication of LASIK refractive surgery.
7. The method of claim 1, wherein the anti-lymphangiogenic agent is purified or isolated.
8. The method of claim 1, wherein said anti-lymphangiogenic agent is selected from the group consisting of: a nucleic acid molecule, an aptamer, an antisense molecule, an RNAi molecule, a protein, a peptide, a cyclic peptide, an antibody or antibody fragment, a polysaccharide, or a small molecule.
9. The method of claim 1, wherein said anti-lymphangiogenic agent is selected from the group consisting of a VEGFR-3 inhibitor, a VEGF-D inhibitor and a VEGF-C inhibitor.
10. The method of claim 9, wherein the anti-lymphangiogenic agent is selected from the group consisting of a VEGF-C antibody, a VEGF-D antibody, a VEGF-R3 antibody, and a polypeptide comprising a soluble VEGFR-3 fragment that binds VEGF-C or VEGF-D.
11-14. (canceled)
15. The method of claim 10, wherein the anti-lymphangiogenic agent is antibody that competitively inhibits the binding of antibody 69D09 to VEGF-C.
16. The method of claim 10, wherein the anti-lymphangiogenic agent is a VEGF-D antibody.
17. The method of claim 16, wherein the VEGF-D antibody is selected from the group consisting of antibodies 2F8, 4A5(VD1), 4E10, 5F12, 4H4, 3C10 28AT743.288.48, MM0001-7E79, RM0007-8C35, 78902, 78939 and 90409.
18. The method of claim 10, wherein the anti-lymphangiogenic agent is a soluble VEGFR-3 fragment that binds VEGF-C or VEGF-D.
19. The method of claim 10, wherein the anti-lymphangiogenic agent is a human or humanized antibody.
20. The method according to claim 1, wherein the anti-lymphangiogenic agent is a VEGFR-2 inhibitor.
21. The method of claim 1, wherein said composition further comprises a molecule that inhibits an activity of an inflammatory cytokine selected from the group consisting of IL-1, IL-7, IL23, IL-6 and TNF-a.
22. The method of claim 1, wherein the method further comprises administering an antibiotic to the human.
23. The method of claim 22, wherein the antibiotic is selected from the group consisting of amikacin, gentamicin, kanamycin, neomycin, netilmicin, streptomycin, tobramycin, teicoplanin, vancomycin, azithromycin, clarithromycin, clarithromycin, dirithromycin, erythromycin, roxithromycin, troleandomycin, amoxicillin, ampicillin, azlocillin, carbenicillin, clozacillin, dicloxacillin, flucozacillin, meziocillin, nafcillin, penicillin, piperacillin, ticarcillin, bacitracin, colistin, polymyxin B, ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, moxifloxacin, norfloxacin, oflazacin, trovafloxacin, mafenide, sulfacetamide, sulfamethizole, sulfasalazine, sulfisoxazole, trimethoprim, cotrimoxazole, demeclocycline, soxycycline, minocycline, oxytetracycline, or tetracycline.
24. The method of claim 1, wherein the eye comprises a tissue or gland in or around the eye selected from the group consisting of ocular tissue, eyelids of the subject, ocular surface, meibomian gland and or lacrimal gland of the human.
25. The method of claim 1, wherein said composition is administered topically to the eye.
26. The method of claim 1, wherein said composition is in the form of a solid, a paste, an ointment, a gel, a liquid, an aerosol, a mist, a polymer, a film, an emulsion, or a suspension.
27. The method of claim 1, wherein the composition further comprises a compound selected from the group consisting of physiological acceptable salt, poloxamer analogs with carbopol, carbopol/hydroxypropyl methyl cellulose (RP MC), carbopol-methyl cellulose, carboxymethylcellulose (CMC), hyaluronic acid, cyclodextrin, and petroleum.
Description:
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of priority U.S. Provisional Application Nos. 61/308,091, 61/329,845 and 61/331,278, which were filed on Feb. 25, 2010, Apr. 30, 2010 and May 4, 2010, respectively. The disclosure of each of the priority applications is incorporated herein by reference in their entireties.
FIELD OF THE INVENTION
[0003] This invention relates generally to the field of ophthalmology.
BACKGROUND OF THE INVENTION
[0004] Dry Eye Disease (DED) is a relatively common condition characterized by inadequate tear film protection of the cornea. Dry eye symptoms have traditionally been managed with eyelid hygiene, topical antibiotics (erythromycin or bacitracin ointments), oral tetracyclines (tetracycline, doxycycline, or minocycline), anti-inflammatory compounds (cyclosporine) and corticosteroids which are often time consuming, frustrating, and frequently ineffective or variably effective treatments.
[0005] Tens of millions of people (mostly women) are affected worldwide by dry eye. 10 million people in US are affected with severe dry eyes with more than 3.2 million women and 1.6 million men above the age of 50 years being affected by dry eye in the US. DED is a potentially disabling disease adversely impacting the vision-related quality of life. It leads to ocular discomfort, a degradation in visual performance (reading speed, contrast sensitivity) and a loss of productivity. Current therapeutic options are limited and costly. Topical cyclosporine-A (Restasis®) is the only approved treatment for DED in US. Despite the high incidence of DED, there is currently no consistently effective treatment for this condition and it still remains a therapeutic challenge. As such, there is a need for new therapeutic modalities to treat DED.
SUMMARY OF THE INVENTION
[0006] The present invention discloses a novel method for the treatment of dry eye disease in humans comprising local application of an anti-lymphangiogenic agent onto the ocular surface. The present invention is based on novel evidence for the selective growth of lymphatic vessels in DED cornea. Additionally, significant increase in both caliber and extent of lymphatics in DED corneas is accompanied by over expression of lymphangiogenic receptor VEGFR-3, further correlating DED with lymphangiogenesis.
[0007] An anti-lymphangiogenic agent of the invention is selected from the group consisting of: a nucleic acid molecule, an aptamer, an antisense molecule, an RNAi molecule, a protein, a peptide, a cyclic peptide, an antibody or antibody fragment, a polysaccharide, and a small molecule.
[0008] In one preferred embodiment of the invention, the anti-lymphangiogenic agent is an inhibitor of VEGF-C or VEGF-D mediated signal transduction by VEGFR-2 or VEGFR-3. Preferably, the amount of the anti-lymphangiogenic agent employed is effective to inhibit the binding of VEGF-C and/or VEGF-D ligand to VEGFR-3 or the stimulatory effect of VEGF-C and/or VEGF-D on VEGFR-3.
[0009] In one aspect of the invention, the inhibitor of VEGF-C or VEGF-D mediated signal transduction by VEGFR-2 or VEGFR-3 is a molecule such as but not restricted to an antibody, a small molecule or a peptide that prevents binding of VEGF-C or VEGF-D to the receptors VEGFR-2 or VEGFR-3.
[0010] In another aspect of the invention, the inhibitor of VEGF-C or VEGF-D mediated signal transduction is a VEGFR-2 or VEGFR-3 soluble receptor. Soluble receptors of VEGFR-2 or VEGFR-3 can be administered directly. Alternatively, increase in the secretion of VEGFR-2 or VEGFR-3 is accomplished by inserting the VEGFR-2 or VEGFR-3 soluble receptors genes into the genome of corneal cells. This could be epithelial cells, keratocytes, fibroblasts, endothelial cells, or bone marrow-derived cells. Methods to introduce genes into a genome of a cell are well-known in the art. Genes are introduced in the genome of corneal cells using viral or non-viral vectors. Viral vectors include for example adenoviruses, retroviruses or lentiviruses. Non-viral vectors include, for example, liposomes such as cationic lipids, nanoparticles, lipoplexes and polyplexes (complexes of polymers with DNA).
[0011] In some embodiments, the anti-lymphangiogenic agent is a VEGF-C antibody, wherein the antibody comprises a heavy chain variable region set forth in amino acids 1-118 of SEQ ID NO: 34 or a heavy chain comprising the amino acid sequence of SEQ ID NO: 34. In some embodiments, the EGF-C antibody is selected from the group consisting of antibodies 69D09, 103, MM0006-2E65 and 193208.
[0012] In alternative embodiments, the anti-lymphangiogenic agent is antibody that competitively inhibits the binding of antibody 69D09 to VEGF-C.
[0013] In some embodiments, the anti-lymphangiogenic agent is a VEGF-D antibody selected from the group consisting of antibodies 2F8, 4A5(VD1), 4E10, 5F12, 4H4, 3C10 28AT743.288.48, MM0001-7E79, RM0007-8C35, 78902, 78939 and 90409.
[0014] In some embodiments, the anti-lymphangiogenic agent is a human or humanized antibody.
[0015] In other embodiments, the anti-lymphangiogenic agent is a soluble VEGFR-3 fragment that binds VEGF-C or VEGF-D.
[0016] In still other embodiments, the anti-lymphangiogenic agent is a VEGFR-2 inhibitor.
[0017] In one embodiment of the invention, the anti-lymphangiogenic agent is administered in combination with an anti-inflammatory agent such as, but not limited to, a composition inhibiting the activity of an inflammatory cytokine selected from the group comprising IL-1,IL-17, TNF-a and IL-6.
[0018] Exemplary functional blockers of IL-1 are described in WO/2009/025763. Exemplary functional blockers of TNF-a include, but are not limited to, recombinant and/or soluble TNF-a receptors, monoclonal antibodies, and small molecule antagonists and/or inverse agonists. One or more commercially-available TNF-a blocking agents are reformulated for topical administration in this embodiment. Exemplary commercial TNF-a blocking agents used for reformulation include, but are not limited to, etanerept/Ernbrel, infliximab/Remicade, and adalimumab/Humira.
[0019] In one embodiment of the invention, the anti-lymphangiogenic agent is administered in combination with an antiobiotic. Exemplary antibiotic compositions used for combination-therapy with antagonists of IL-mediated inflammation include but are not limited to, amikacin, gentamicin, kanamycin, neomycin, netilmicin, streptomycin, tobramycin, teicoplanin, vancomycin, azithromycin, clarithromycin, clarithromycin, dirithromycin, erythromycin, roxithromycin, troleandomycin, amoxicillin, ampicillin, azlocillin, carbenicillin, clozacillin, dicloxacillin, flucozacillin, meziocillin, nafcillin, penicillin, piperacillin, ticarcillin, bacitracin, colistin, polymyxin B, ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, moxifloxacin, norfloxacin, oflazacin, trovafloxacin, mafenide, sulfacetamide, sulfamethizole, sulfasalazine, sulfisoxazole, trimethoprim, cotrimoxazole, demeclocycline, soxycycline, minocycline, oxytetracycline, or tetracycline.
[0020] The composition of the invention is locally applied to the ocular tissue, alternatively the composition of the invention is applied to the eyelids, the ocular surface, the meibomian glands or the lacrimal glands.
[0021] The composition can be in the form of a solid, a paste, an ointment, a gel, a liquid, an aerosol, a mist, a polymer, a film, an emulsion, or a suspension.
[0022] Optionally, the composition further contains a compound selected from the group consisting of a physiological acceptable salt, poloxamer analogs with carbopol, carbopol/hydroxypropyl methyl cellulose (RP MC), carbopol-methyl cellulose, carboxymethylcellulose (CMC), hyaluronic acid, cyclodextrin, and petroleum.
[0023] Dry eye disease may be attributable to a number of factors, and treatment of subjects who have developed dry eye disease due to a variety of specific factors is contemplated. In some variations, the DED to be treated is DED caused by any condition other than an alloimmune response. Alloimmune responses may result, for example, in some corneal transplant patients. More specifically, in some variations, the DED to be treated is an autoimmune DED or a DED associated with Sjogren's syndrome. In some variations, the DED is due to excessively fast tear evaporation (evaporative dry eyes) or inadequate tear production. In some variations, the dry eye disease is attributable to one or more causes selected from: aging, contact lens usage and medication usage. In some variations, the dry eye disease is a complication of LASIK refractive surgery. In other variations, the DED arises in a subject who has not had eye surgery of any kind, e.g., treatment of subjects in whom the DED is caused by LASIK surgery, corneal transplant surgery, or other ocular surgeries.
DESCRIPTION OF THE DRAWINGS
[0024] FIG. 1: Representative whole mount corneal immunofluorescence micrographs showing lymphatics (CD31lo/LYVE-1hi) in normal and dry eye (DE) at day 14 (20× magnification).
[0025] FIG. 2: Representative whole mount corneal immunofluorescence micrographs showing lymphatics (CD31lo/LYVE-1hi) in normal and dry eye (DE) at days 6, 10 and 14 (100× magnification).
[0026] FIG. 3A-3B: Quantification of lymphatics in dry eye (DE) corneas. Morphometric analysis of corneal lymphangiogenesis in normal and DE days 6, 10 and 14 (100× magnification). Morphometric evaluation showed significant increase in lymphatic area (LA) in dry eye compared to normal corneas (FIG. 3a). Significant increase in lymphatic caliber (LC) in dry eye compared to normal corneas was noticed only at day 14 (FIG. 3b). Data from a representative experiment of three performed is shown as mean±S.E.M and each group consists of four to five mice.
[0027] FIG. 4: Analysis of lymphangiogenic-specific growth factors. Real-time PCR analysis showing transcript levels of VEGF-A, VEGF-C and VEGF-D in the dry eye corneas at different time points. A significant increase in VEGF-D was seen at day 6 whereas VEGF-A and VEGF-C increased significantly only by day 14. Data from a representative experiment of three performed is shown as mean±S.E.M and each group consists of four to five mice.
[0028] FIG. 5: Analysis of lymphangiogenic-specific growth factor receptors. Real-time PCR analysis showing transcript levels of VEGFR-2 and VEGFR-3 in the dry eye corneas at different time points. Significant increase in VEGFR-3 was seen earliest at day 6 but VEGFR-2 increased significantly later in disease at day 14. Data from a representative experiment of three performed is shown as mean±S.E.M and each group consists of four to five mice.
[0029] FIG. 6: Enuneration of corneal CD11b.sup.+/LYVE-1.sup.+ cells. A significant increase in the number of both CD11b.sup.+ and double stained CD11hi/LYVE-1.sup.+ cells in the dry eye corneas as compared to normal. Data from a representative experiment of three performed is shown as mean±S.E.M and each group consists of four to five mice.
[0030] FIG. 7: Increased homing of mature MTIC-II+CD11b+ APC in the draining LN of DED mice. Flow cytometric analysis of draining lymph nodes showing significant increase in the frequencies of mature MHC-II.sup.+ CD11b.sup.+ APC in DED mice compared with normal mice. Data from a representative experiment of two performed is shown and each group consists of three mice.
[0031] FIG. 8: Analysis of lymphangiogenic-specific growth factors and their receptors. Real-time PCR analysis showing transcript levels of VEGF-A, VEGF-C, VEGF-D, VEGFR-2 and VEGFR-3 in the dry eye corneas.
[0032] FIG. 9: Analysis of proinflammatory cytokines in conjunctiva. Real-time PCR analysis showing expression of cytokines IL-la, IL-10, IL-6, IL-17. The levels of all four cytokines in the conjunctiva showed significantly decreased expression in anti-VEGF-C treated DED mice as compared to those of untreated DED mice
[0033] FIG. 10: Analysis of inflammatory cytokines in draining lymph nodes. Real-time PCR analysis for IL-17 (Th17 cells) and IFN-γ (Th1 cells). Draining lymph nodes of anti-VEGF-C treated DED mice showed significantly decreased induction of T-cell mediated autoimmune response compared untreated DED mice.
[0034] FIG. 11: Enumeration of CD11b.sup.+ cells in DED corneas. Treatment with anti-VEGF-C antibodies significantly decreased infiltration of CD11b.sup.+ cells (30%) in the DED corneas (day 14).
[0035] FIG. 12: Epifluorescent microscopic image of corneal wholemounts immunostained with CD31 and LYVE-1.
[0036] FIG. 13: Quantification of number of infiltrating CD11b+ cells per mm2 of cornea.
[0037] FIG. 14: In vivo blockade of VEGF-C ameliorates clinical signs of DED. Corneal fluorescein staining (CFS) score is used as readout for the clinical signs of dry eye inflammation, in anti-VEGF-C Ab-treated and untreated mice. CFS scores were significantly decreased in the group treated with anti-VEGF-C antibody at days 5, 9 and 13 vs the untreated group. Data shown as mean±S.E.M and each group consisted of 3-4 mice.
DETAILED DESCRIPTION
Dry Eye
[0038] Keratoconjunctivitis sicca (KCS), also called keratitis sicca, sicca syndrome, xerophthalmia, dry eye syndrome (DES),or simply dry eyes, is an eye disease caused by decreased tear production or increased tear film evaporation commonly found in humans and some animals. Typical symptoms of keratoconjunctivitis are dryness, burning and a sandygritty eye irritation that gets worse as the day goes on.
[0039] Keratoconjunctivitis sicca is characterized by inadequate tear film protection of the cornea because of either inadequate tear production or abnormal tear film constitution, which results in excessively fast evaporation or premature destruction of the tear film. The tear film is constituted by 3 layers: (1) a lipid layer, produced by the Meibomian glands; (2) an aqueous layer, produced by the main and accessory lacrimal glands; and (3) a hydrophilic mucin layer, produced by the conjunctival goblet cells. Any abnormality of 1 of the 3 layers produces an unstable tear film and symptoms of keratitis sicca.
[0040] Sjogren's syndrome and autoimmune diseases associated with Sjogren's syndrome are also conditions associated with aqueous tear deficiency. Drugs such as isotretinoin, sedatives, diuretics, tricyclic antidepressants, antihypertensives, oral contraceptives, antihistamines, nasal decongestants, beta-blockers, phenothiazines, atropine, and pain relieving opiates such as morphine can cause or worsen this condition. Infiltration of the lacrimal glands by sarcoidosis or tumors, or postradiation fibrosis of the lacrimal glands can also cause this condition.
[0041] Keratoconjunctivitis sicca can also be caused by abnormal tear composition resulting in rapid evaporation or premature destruction of the tears. When caused by rapid evaporation, it is termed evaporative dry eyes. In this, although the tear gland produces a sufficient amount of tears, the rate of evaporation of the tears is too rapid. There is a loss of water from the tears that results in tears that are too "salty" or hypertonic. As a result, the entire conjunctiva and cornea cannot be kept covered with a complete layer of tears during certain activities or in certain environments.
[0042] Aging is one of the most common causes of dry eyes. About half of all people who wear contact lenses complain of dry eyes. There are two potential connections between contact lens usage and dry eye. Traditionally, it has been believed that soft contact lenses, which float on the tear film that covers the cornea, absorb the tears in the eyes. However, it is also now known that contact lens usage damages corneal nerve sensitivity, which may lead to decreased lacrimal gland tear production and dry eye. The effect of contact lenses on corneal nerve sensitivity is well established for hard contact lenses as well as soft and rigid gas permeable contact lenses. The connection between this loss in nerve sensitivity and tear production is the subject of current research. Dry eyes also occur or get worse after LASIK and other refractive surgeries. The corneal nerves stimulate tear secretion. Dry eyes caused by these procedures usually resolves after several months. Persons who are thinking about refractive surgery should consider this.
[0043] A variety of approaches can be taken to treat dry eyes. These can be summarized as: avoidance of exacerbating factors, tear stimulation and supplementation, increasing tear retention, eyelid cleansing and treatment of eye inflammation. Application of artificial tears every few hours can provide temporary relief. Inflammation occurring in response to tears film hypertonicity can be suppressed by mild topical steroids or with topical immunosuppressants such as cyclosporine. Consumption of dark-fleshed fish containing dietary omega-3 fatty acids is associated with a decreased incidence of dry eyes syndrome in women. Early experimental work on omega-3 has shown promising results when used in a topical application (Rashid S et al (2008). Arch Ophthalmo1126 (2): 219-225).
[0044] DED is increasingly recognized as an immune-mediated disorder. Desiccating stress in DED initiates an immune-based inflammation response that is sustained by the ongoing interplay between the ocular surface and various pathogenic immune cells, primarily the CD4+ cells in the conjunctivia and the CD11b+ monocytic cells in the corneal. Desiccating stress induces secretion of inflammatory cytokines, especially IL-1, TNF-a and IL-6 by ocular tissues, which facilitates the activation and migration of resident antigen presenting cells (APCs) toward the regional draining lymph nodes (LNs). In the LNs, these APCs stimulate naive T-cells, leading to the expansion of IL-17 secreting Th17 cells and interferon (IFN)-y-secreting Th1 cells. Once these effectors are generated in the LNs, they migrate to the ocular surface and secrete effector cytokines.
VEGF
[0045] VEGF (Vascular Endothelial Growth Factor) is a sub-family of growth factors, specifically the platelet-derived growth factor family of cystine-knot growth factors. They are important signaling proteins involved in both vasculogenesis (the de novo formation of the embryonic circulatory system) and angiogenesis (the growth of blood vessels from pre-existing vasculature). Members of the platelet-derived growth factor family include the Placenta growth factor (PIGF), VEGF-A (also known as VEGF), VEGF-B, VEGF-C, VEGF-D and VEGF-E.
[0046] VEGF-A, VEGF-C and VEGF-D exert their effects by variously binding to and activating structurally related membrane receptor tyrosine kinases; VEGF receptor-1 (VEGFR-1 or Flt-I), VEGFR-2 (flk-1 or KDR), and VEGFR-3 (Flt-4). Members of the VEGF family may also interact with the structurally distinct receptor neuropilin-1. Binding of a VEGF to these receptors initiates a signaling cascade, resulting in effects on gene expression and cell survival, proliferation, and migration.
[0047] VEGF-A binds to VEGFR-1 (Flt-1) and to VEGFR-2 (KDR/Flk-1). VEGFR-2 appears to mediate almost all of the known cellular responses to VEGF-A. The function of VEGFR-1 is less well-defined, although it is thought to modulate VEGFR-2 signaling. VEGF-A is believed to play a central role in the development of new blood vessels (angiogenesis) and the survival of immature blood vessels (vascular maintenance).
[0048] VEGF-C and VEGF-D are ligands for VEGFR-2 and VEGFR-3 and are involved in the mediation of lymphangiogenesis.
Lymphangiogenesis
[0049] Lymphangiogenesis refers to formation of lymphatic vessels, particularly from pre-existing lymphatic vessels, but as used herein, the term applies to formation of lymph vessels under any condition. It also applies to the enlargement of lymphatic vessels, commonly known as lymphatic hyperplasia. Lymphangiogenesis plays an important physiological role in homeostasis, metabolism and immunity. Lymphatic vessel formation has also been implicated in a number of pathological conditions including neoplasm metastasis, oedema, rheumatoid arthritis, psoriasis and impaired wound healing.
[0050] The normal human cornea is avascular, thus suppressing the afferent lymphatic and efferent vascular arms or the immune cycle. Inflammation however negates this immune and angiogenic privileged state of the cornea and giving the corneal and ocular surface the potential to mount an immune response. Our results show that corneal lymphatics play an important role in mediating the corneal inflammation in dry eyes. Inhibition of corneal lymphangiogenesis decreases ocular surface inflammation in a well characterized mouse model of DED.
[0051] Lymphangiogenesis is regulated to a large extent by VEGF-C and VEGF-D. Lymphangiogenesis appears to be regulated by signaling mediated by VEGFR-3, particularly upon specifically binding its ligands, VEGF-C and VEGF-D. VEGF-C and VEGF-D are two of six members of a family of angiogenic regulators. Other members are VEGF-A (also known as VEGF), VEGF-B, VEGF-E and placental growth factor (P1GF).
[0052] During embryogenesis, lymphatic endothelial cell sprouting, proliferation and survival is promoted by VEGF-C. Lymphatic vessels fail to develop in mice in which VEGF-C is absent (Vegfc knockout mice), and such mice develop severe edema. Indeed, absence of VEGF-C is embryonic lethal. Lymphatic vessel hypoplasia and lymphedema is exhibited in the skin of mice hemizygous for Vegfc (i.e. mice possessing one functional allele).
[0053] Lymphangiogenesis is also partly regulated by VEGF-D, similar to VEGF-C. However, lymphangiogenesis during embryonic development is not dependent upon VEGF-D, as demonstrated by Vegfd knockout mice. The lymphatic system in Vegfd knockout mice is relatively normal and Vegfd knockout mice are viable and fertile. The absolute abundance of lymphatic vessels in the lung is, however, reduced by approximately 30% compared to wild-type mice.
[0054] Lymphatic vessels express VEGFR-3, the receptor for VEGF-C and VEGF-D, and both VEGF-C and VEGF-D signal predominantly through VEGFR-3. It is also becoming apparent that lymphatic vessels variously express VEGFR-2. VEGF-C and VEGF-D are synthesized as prepro-polypeptides and are proteolytically processed by proprotein convertases. In humans, mature proteolytically processed forms of VEGF-C and VEGF-D bind to VEGFR-2 and VEGFR-3. In mice, mature VEGF-D binding is restricted to VEGFR-3.
[0055] VEGF-C and VEGF-D exist as homodimers, and it has been suggested that they may exist as VEGF-C-VEGF-D heterodimers. In addition to lymphatic vessels, VEGFR-3 is also expressed on blood vessel endothelial cells during development, thereby accounting for the severe vasculogenic and angiogenic defects observed during early embryogenesis in models comprising inactive VEGFR-3 signaling. The lymphatic system possesses almost exclusive expression of VEGFR-3 in healthy tissues in adulthood, because VEGFR-3 expression in blood vessels declines following birth and during adolescence. Thus, only lymphangiogenesis is inhibited in adults by inhibition of the VEGF-C-VEGF-D-VEGFR-3 signaling axis.
[0056] Lymphatic vessels express neuropilin-2 (NRP-2), which can bind VEGF-C or VEGF-D. In lymphangiogenesis, NRP-2 is thought to act as a co-receptor to increase the binding affinity of VEGF-C or VEGF-D to VEGFR-3. NRP-2 is required for lymphangiogenesis. Proliferation of lymphatic vessel endothelial cells was reduced and lymphatic vessels and capillaries failed to develop in Nrp2 knockout mice in which NRP-2 is absent. Similarly, NRP-1 is capable of binding VEGF-C and VEGF-D.
[0057] Defective lymphatic capillaries are the underlying cause of Milroy disease and other rare hereditary forms of lymphedema in humans. Tyrosine kinase-inactivating point mutations of the VEGFR-3 gene have been identified as a major cause of Milroy disease, and VEGF-C and VEGF-D therapy has shown promising efficacy in preclinical animal models. However, previous work has only demonstrated lymphatic capillary reconstitution, whereas effects on the collecting lymphatic vessels that are more commonly damaged in lymphedema have not been addressed.
[0058] Lymphatic vessel growth in adult tissues can be induced by Angiopoietin-1 (ANG-1) through its binding to the tunica interna endothelial cell kinase receptor 2 (TIE-2 or TEK). Lymphatic vessel sprouting that was induced by ANG-1 was inhibited by an inhibitor of VEGFR-3. Furthermore, VEGFR-3 was up-regulated by ANG-1 binding to TIE-2. TIE-2 expressed on lymphatic vascular endothelial cells may also be agonized by ANG-2 and ANG-3.
[0059] VEGF-C and VEGF-D may act as ligands for integrins. Specifically, VEGF-C and VEGF-D have been shown to act as ligands for integrin α9β1. Cell adherence and cell migration were promoted by each of VEGF-C and VEGF-D in cells expressing integrin quadrature9quadrature1. The effect could be blocked by an anti-integrin α9β1 antibody or siRNA directed to integrin α9β1.
[0060] Thus, in lymphangiogenesis, VEGFR-3 appears to be central. VEGFR-3 specifically binds and is activated by ligands VEGF-C and VEGF-D. VEGF-C and VEGF-D are synthesized as prepro-polypeptides and are activated by proteolytic processing by proprotein convertases. VEGF-C and VEGF-D also bind specifically to NRP-2, which is thought to be a co-receptor for VEGFR-3. Both lymphangiogenesis and VEGFR-3 are up-regulated when ANG-1 specifically binds to TIE-2. It is thought that binding of VEGF-C or VEGF-D to integrins, particularly integrin α9β1, also performs a role in lymphangiogenesis.
[0061] Lymphangiogenesis is mediated primarily by the interaction of growth factors VEGF-C and VEGF-D on VEGFR-2 and VEGFR-3, and in particular VEGFR-3. VEGF-A also contributes, albeit indirectly, to lymphangiogenesis by recruiting VEGF-C and VEGF-D secreting macrophages. Inhibition of VEGF-C and VEGF-D signaling pathways would thus constitute a new approach to the treatment of DED. The invention is however not restricted to the inhibition of VEGF-C and VEGF-D signaling pathways and according to the present invention, other anti-lymphangiogenic agents can be used to reduce the signs and symptoms of DED.
Anti-lymphangiogenic Agents
[0062] Persons skilled in the art will appreciate from the foregoing that inhibition of lymphangiogenesis can occur at a variety of biological points comprising any one or more of the interactions described. For example, inhibition may occur by targeting VEGF-D, VEGF-C or VEGFR-3.
[0063] An "anti-lymphangiogenic agent" is any substance that partially or fully blocks, neutralizes, reduces, inhibits or antagonizes a biological activity of a molecular component of signaling mediated by VEGFR-3 or lymphangiogenesis. Alternatively, an anti-lymphangiogenic agent is any substance that partially or fully blocks, neutralizes, reduces, inhibits or antagonizes a VEGF-C or VEGF-D biological activity. Thus, "inhibition" is the corresponding state elicited by an inhibitor. A molecular component of signaling mediated by VEGFR-3 or lymphangiogenesis includes VEGFR-3, VEGFR-2, VEGF-C, VEGF-D, proprotein convertases, neuropilin-1 (NRP-1), neuropilin-2 (NRP-2), angiopoietin-1 (ANG-1), tunica interna endothelial cell kinase receptor (TIE-2) or integrin α9β1.
[0064] It is envisaged that practice of the invention extends to any inhibitor known now or in the future.
[0065] Suitable classes of inhibitor molecules that target VEGF-C or VEGF-D or signaling mediated by VEGFR-3, or lymphangiogenesis include antibodies, polypeptides, peptides, peptide mimetics, nucleic acid molecules, and small molecules. Such classes of inhibitor molecules are suitable also for inhibiting binding of ligands, for example VEGF-C or VEGF-D, to integrins, particularly integrin α9β1.
[0066] Suitable VEGF-C, VEGF-D, VEGFR-3-mediated signaling or lymphangiogenesis antibody inhibitors include antagonist and neutralizing antibodies or antibody fragments.
[0067] Polypeptide, peptide, or peptide mimetic VEGF-C or VEGF-D inhibitors, VEGFR-3-mediated signaling inhibitors or lymphangiogenesis inhibitors include fragments or amino acid sequence variants of native polypeptide or peptide components of VEGF-C, VEGF-D, VEGFR-3-mediated signaling or lymphangiogenesis.
[0068] Nucleic acid molecule inhibitors of VEGF-C or VEGF-D activity, VEGFR-3-mediated signaling or lymphangiogenesis include antisense molecules, nucleic acids in triple-helix formation, small interfering RNA (siRNA), and ribozymes.
[0069] Small molecule inhibitors of VEGF-C or VEGF-D, VEGFR-3-mediated signaling or lymphangiogenesis include organic and inorganic molecules.
[0070] Inhibitors of VEGF-C or VEGF-D activity, VEGFR-3-mediated signaling or lymphangiogenesis according to the present invention may exert their effects by interacting with any one or more of VEGFR-3, VEGFR-2, VEGF-C, VEGF-D, proprotein convertases, NRP-1, NRP-2, ANG-1, TIE-2 or integrins, particularly integrin a9131, in their DNA, RNA or polypeptide forms.
[0071] Inhibition of VEGF-C or VEGF-D activity, VEGFR-3-mediated signaling or lymphangiogenesis according to the present invention may occur via inhibition of ligand availability for receptor binding, inhibition of receptor availability for ligand binding, inhibition of receptor tyrosine kinase activity, or inhibition of co-receptor interaction.
[0072] As used herein, "availability" refers to the potential or actual amount of a molecule that performs some function in VEGF-C or VEGF-D activity, VEGFR-3-mediated signaling or lymphangiogenesis and is present in a biological system. Availability may be relative or absolute. For example, if all copies of a gene encoding a polypeptide involved in lymphangiogenesis were rendered non-functional by genetic mutation and no functioning polypeptide was synthesized, then there would be no availability of the polypeptide in an absolute sense. Alternatively, if the same gene was present with one functioning copy and 50% of the polypeptide was synthesized, there would be reduced or inhibited availability in a relative sense. Similarly, other mechanisms may be envisaged where availability is affected. Receptors may be transcribed or translated to a lesser degree when compared with a control, or the receptor may be targeted by an antibody that binds specifically to the ligand binding site, thereby reducing or inhibiting receptor availability for ligand binding. Analogously, if ligand synthesis is targeted by an antisense inhibitor, or if an antibody inhibitor or soluble receptor inhibitor specifically binds to the ligand, then there will be reduction or inhibition of ligand availability for receptor binding.
[0073] The term "specific binding" or "specifically binds" or "specific for" refers to binding where a molecule binds to a particular polypeptide or epitope on a particular polypeptide without substantially binding to any other polypeptide or polypeptide epitope. Such binding is measurably different from a non-specific interaction. Specific binding can be measured, for example, by determining binding of a molecule compared to binding of a control molecule, which generally is a molecule of similar structure that does not have binding activity. For example, specific binding can be determined by competition with a control molecule that is similar to the target, for example, an excess of non-labeled target. In this case, specific binding is indicated if the binding of the labeled target to a probe is competitively inhibited by excess unlabeled target. As used herein, specific binding is used in relation to the interaction between the molecular components of VEGF-C or VEGF-D activity, VEGFR-3-mediated signaling or lymphangiogenesis. Specific binding is also used in relation to the interaction between the molecular components of VEGF-C or VEGF-D activity, VEGFR-3-mediated signaling or lymphangiogenesis and agents that partially or fully block, neutralize, reduce or antagonize a biological activity of a molecule that facilitates VEGFR-3-mediated signaling or lymphangiogenesis. Specific binding also applies to the interaction between the molecular components of VEGF-C or VEGF-D activity and agents that partially or fully block, neutralize, reduce or antagonize VEGF-C or VEGF-D biological activity.
[0074] In particular, specific binding refers to a molecule having a Kd at least 2-fold less for the particular polypeptide or epitope on a particular polypeptide than it does for a non-specific target. Preferably, specific binding refers to a molecule having a Kd at least 4-fold, 6-fold, 8-fold or 10-foldless for the particular polypeptide or epitope on a particular polypeptide than it does for a non-specific target. Alternatively, specific binding can be expressed as a molecule having a Kd for the target of at least about 10-4 M, alternatively at least about 10-5 M, alternatively at least about 10.sup.'6 M, alternatively at least about 10-7 M, alternatively at least about 10-8 M, alternatively at least about 10-9 M, alternatively at least about 10-10 M, alternatively at least about 10-11 M, alternatively at least about 10-12 M, or less.
[0075] The person skilled in the art will appreciate that there exist many mechanisms for inhibiting VEGF-C or VEGF-D activity, VEGFR-3-mediated signaling or lymphangiogenesis. The principal aim is to reduce receptor signaling. Some examples will be described below, but such a list is not intended to be limiting.
Antibody Inhibitors
[0076] The term "antibody" is used in the broadest sense and specifically covers, for example, polyclonal antibodies, monoclonal antibodies (including antagonist and neutralizing antibodies), antibody compositions with polyepitopic specificity, single chain antibodies, and fragments of antibodies, provided that they exhibit the desired biological or immunological activity.
[0077] An "antibody inhibitor" will specifically bind to a particular polypeptide or epitope on a particular polypeptide without substantially binding to any other polypeptide or polypeptide epitope. Such binding will partially or fully block, neutralize, reduce or antagonize VEGF-C or VEGF-D activity or a biological activity of a molecule that facilitates VEGFR-3-mediated signaling or lymphangiogenesis. Such target molecules include VEGFR-3, VEGFR-2, VEGF-C and VEGF-D, for example.
[0078] An "isolated antibody" is one which has been identified and separated and/or recovered from a component of its natural environment. Contaminant components of its natural environment are materials which would interfere with diagnostic or therapeutic uses for the antibody, and may include enzymes, hormones, and other proteinaceous or non-proteinaceous solutes. Generally, the antibody will be purified (1) to greater than 95% by weight of antibody as determined by the Lowry method, and most preferably more than 99% by weight, (2) to a degree sufficient to obtain at least 15 residues of N terminal or internal amino acid sequence by use of a spinning cup sequenator, or (3) to homogeneity by SDS PAGE under reducing or non-reducing conditions using Coomassie blue or, preferably, silver stain. An isolated antibody includes the antibody in situ within recombinant cells since at least one component of the antibody's natural environment will not be present. Ordinarily, however, isolated antibody will be prepared by at least one purification step.
[0079] Where antibody fragments are used, the smallest inhibitory fragment that specifically binds to the binding domain of the target protein is preferred.
[0080] Polyclonal Antibodies
[0081] Polyclonal antibodies are preferably raised in animals by multiple subcutaneous (s.c.) or intraperitoneal (i.p.) injections of the relevant antigen and an adjuvant. It may be useful to conjugate the relevant antigen (especially when synthetic peptides are used) to a protein that is immunogenic in the species to be immunized. For example, the antigen can be conjugated to keyhole limpet hemocyanin (KLH), serum albumin, bovine thyroglobulin, or soybean trypsin inhibitor, using a bifunctional or derivatizing agent, e.g., maleimidobenzoyl sulfosuccinimide ester (conjugation through cysteine residues), N-hydroxysuccinimide (through lysine residues), glutaraldehyde, succinic anhydride, SOCl2, or R1N═C═NR, where R and R1 are different alkyl groups.
[0082] In one protocol for generating polyclonal antibodies, animals are immunized against the antigen, immunogenic conjugate, or derivative, by combining the antigen, conjugate or derivative with 3 volumes of Freund's complete adjuvant and injecting the solution intradermally at multiple sites. One month later, the animals are boosted with 1/5 to 1/10 the original amount of peptide or conjugate in Freund's complete adjuvant by subcutaneous injection at multiple sites. Seven to 14 days later, the animals are bled and the serum is assayed for antibody titer. Animals are boosted until the titer plateaus. Conjugates also can be made in recombinant cell culture as protein fusions. Also, aggregating agents such as alum are suitably used to enhance the immune response.
[0083] Monoclonal Antibodies
[0084] The term "monoclonal antibody" as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic site. Furthermore, in contrast to polyclonal antibody preparations which include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen. In addition to their specificity, the monoclonal antibodies are advantageous in that they may be synthesized uncontaminated by other antibodies. The modifier "monoclonal" is not to be construed as requiring production of the antibody by any particular method.
[0085] Monoclonal antibodies may be made using the hybridoma method in which a mouse or other appropriate host animal, such as a hamster, is immunized to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the protein used for immunization. Alternatively, lymphocytes may be immunized in vitro. After immunization, lymphocytes are isolated and then fused with a myeloma cell line using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell.
[0086] The hybridoma cells thus prepared are seeded and grown in a suitable culture medium, which preferably contains one or more substances that inhibit the growth or survival of the unfused, parental myeloma cells (also referred to as fusion partner).
[0087] Culture medium in which hybridoma cells are growing is assayed for production of monoclonal antibodies directed against the antigen. Preferably, the binding specificity of monoclonal antibodies produced by hybridoma cells is determined by immunoprecipitation or by an in vitro binding assay, such as radioimmunoassay (RIA) or enzyme-linked immunosorbent assay (ELISA).
[0088] Once hybridoma cells that produce antibodies of the desired specificity, affinity, and/or activity are identified, the clones may be subcloned by limiting dilution procedures and grown by standard methods. In addition, the hybridoma cells may be grown in vivo as ascites tumors in an animal e.g., by i.p. injection of the cells into mice.
[0089] The monoclonal antibodies secreted by the subclones are suitably separated from the culture medium, ascites fluid, or serum by conventional antibody purification procedures such as, for example, affinity chromatography (e.g., using protein A or protein G-Sepharose) or ion-exchange chromatography, hydroxyapatite chromatography, gel electrophoresis, or dialysis.
[0090] DNA encoding the monoclonal antibodies is readily isolated and sequenced using conventional procedures. The hybridoma cells serve as a preferred source of such DNA. Once isolated, the DNA may be placed into expression vectors, which are then transfected into host cells such as E. coli cells, simian COS cells, Chinese Hamster Ovary (CHO) cells, or myeloma cells that do not otherwise produce antibody protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells.
[0091] Monoclonal antibodies or antibody fragments can be isolated from antibody phage libraries. High affinity (nM range) human antibodies can be generated by chain shuffling, as well as combinatorial infection and in vivo recombination as a strategy for constructing very large phage libraries. Thus, these techniques are viable alternatives to traditional monoclonal antibody hybridoma techniques for isolation of monoclonal antibodies.
[0092] The DNA that encodes the antibody may be modified to produce chimeric or fusion antibody polypeptides. The monoclonal antibodies used herein include "chimeric" antibodies in which a portion of the heavy and/or light chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired biological activity.
[0093] Human and Humanized Antibodies
[0094] The anti-VEGF-C, anti-VEGF-D, anti-VEGFR-3-mediated signaling or anti-lymphangiogenesis antibodies used in the invention may comprise humanized antibodies or human antibodies. Generally, a "humanized antibody" is an antibody of non-human origin that has been modified using recombinant DNA techniques to circumvent the problem of a human's immune system reacting to an antibody as a foreign antigen. The standard procedure of producing monoclonal antibodies produces mouse antibodies. Although murine antibodies are very similar to human ones, there are differences. Consequently, the human immune system recognizes mouse antibodies as foreign, rapidly removing them from circulation and causing systemic inflammatory effects. "Humanized" forms of non-human (e.g., rodent) antibodies are chimeric antibodies that contain a reduced percentage of sequence derived from the non-human antibody. Various forms of humanized anti-VEGF-C, anti-VEGF-D, anti-VEGFR-3-mediated signaling or anti-lymphangiogenesis antibodies are contemplated. Humanized antibodies may be intact antibodies, such as intact IgG1 antibodies, antibody chains or fragments thereof (such as Fv, Fab, Fab', F(ab')2, or other antigen-binding subsequences of antibodies). Humanized antibodies include human antibodies (recipient antibody) in which residues from a complementary determining region (CDR) of the recipient are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat or rabbit having the desired specificity, affinity and capacity. In some instances, Fv framework residues of the human antibody are replaced by corresponding non-human residues. Humanized antibodies may also comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human antibody and all or substantially all of the FR regions are those of a human antibody consensus sequence. The humanized antibody optimally also will comprise at least a portion of an antibody constant region (Fc), typically that of a human antibody.
[0095] Various humanization strategies have been described in the prior art and it is envisaged that practice of the invention extends to the use of both known humanization strategies and any new strategies to be developed in the future. Examples of known humanization strategies include those described by Studnicka (U.S. Pat. No. 5,869,619) and Padlan (1991, Molec. Immunol., 28, 489-498), Winter (U.S. Pat. No. 5,225,539) and Jones et al (1986, Nature, 321, 522-525), Queen et al. (U.S. Pat. No. 5,693,761) and Foote (U.S. Pat. No. 6,881,557).
[0096] As an alternative to humanization, human antibodies can be generated. For example, it is now possible to produce transgenic animals (e.g., mice) that are capable, upon immunization, of producing a full repertoire of human antibodies in the absence of endogenous immunoglobulin production.
[0097] Alternatively, phage display technology can be used to produce human antibodies and antibody fragments in vitro, from immunoglobulin variable (V) domain gene repertoires from unimmunized donors. Phage display can be performed in a variety of formats. Several sources of V-gene segments can be used for phage display.
[0098] Antibody Fragments
[0099] "Antibody fragments" comprise a portion of an antibody, preferably the antigen binding or variable region of the intact antibody. Examples of antibody fragments include Fab, Fab', F(ab')2, and Fv fragments; diabodies; linear antibodies; single chain antibody molecules; and multispecific antibodies formed from antibody fragments. . Antibody fragments of particular interest are fragments that retain antigen-binding properties of the whole antibody, and are useful as inhibitors for practicing the invention.
[0100] Papain digestion of antibodies produces two identical antigen binding fragments, called "Fab" fragments, and a residual "Fc" fragment, a designation reflecting the ability to crystallize readily. Each Fab fragment is monovalent with respect to antigen binding, i.e., it has a single antigen binding site. Pepsin treatment of an antibody yields a single large F(ab')2 fragment which roughly corresponds to two disulfide linked Fab fragments having divalent antigen binding activity and is still capable of cross linking antigen. Fab' fragments differ from Fab fragments by having additional residues at the carboxy terminus of the CH1 domain including one or more cysteines from the antibody hinge region. Fab'-SH is the designation herein for Fab' in which the cysteine residue(s) of the constant domains bear a free thiol group. F(ab')2 antibody fragments originally were produced as pairs of Fab' fragments which have hinge cysteines between them. Other chemical couplings of antibody fragments are also known.
[0101] "Fv" is the minimum antibody fragment which contains a complete antigen recognition binding site. This fragment consists of a dimer of one heavy and one light chain variable region domain in tight, non covalent association. From the folding of these two domains emanate six hypervariable loops (3 loops each from the H and L chain) that contribute the amino acid residues for antigen binding and confer antigen binding specificity to the antibody. However, even a single variable domain (or half of an Fv comprising only three CDRs specific for an antigen) has the ability to recognize and bind antigen, although at a lower affinity than the entire binding site.
[0102] "Single chain Fv" abbreviated as "scFv" are antibody fragments that comprise the VH and VL antibody domains connected into a single polypeptide chain. Preferably, the scFv polypeptide further comprises a polypeptide linker between the VH and VL domains which enables the scFv to form the desired structure for antigen binding.
[0103] In certain circumstances there are advantages of using antibody fragments, rather than whole antibodies. The smaller size of the fragments allows for rapid clearance from the circulation.
[0104] Various techniques have been developed for the production of antibody fragments. Traditionally, these fragments were derived via proteolytic digestion of intact antibodies. However, these fragments can now be produced directly by recombinant host cells. Fab, Fv and ScFv antibody fragments can all be expressed in and secreted from E. coli, thus allowing the facile production of large amounts of these fragments. Antibody fragments can be isolated from the antibody phage libraries. Alternatively, Fab'-SH fragments can be directly recovered from E. coli and chemically coupled to form F(ab')2 fragments. According to another approach, F(ab')2 fragments can be isolated directly from recombinant host cell culture. Fab and F(ab')2 fragment with increased in vivo half-life comprising a salvage receptor binding epitope residues also may be used.
[0105] Other techniques for the production of antibody fragments will be apparent to the skilled practitioner. The antibody of choice is a single chain Fv fragment (scFv). Fv and scFv are the only species with intact combining sites that are devoid of constant regions; thus, they are suitable for reduced nonspecific binding during in vivo use. The antibody fragment may also be a "linear antibody", which may be monospecific or bispecific. The inhibitor also maybe a polypeptide or protein comprising an antibody or antibody fragment linked to another entity to form a fusion protein.
[0106] Bispecific Antibodies
[0107] Bispecific antibodies are antibodies that have binding specificities for at least two different epitopes. Bispecific antibodies can be prepared as full length antibodies or antibody fragments (e.g., F(ab')2 bispecific antibodies).
[0108] Methods for making bispecific antibodies are known in the art. Traditional production of full length bispecific antibodies is based on the co-expression of two immunoglobulin heavy chain-light chain pairs, where the two chains have different specificities.
[0109] According to a different approach, antibody variable domains with the desired binding specificity (antibody-antigen combining sites) are fused to immunoglobulin constant domain sequences.
[0110] Bispecific antibodies include cross-linked or "heteroconjugate" antibodies. Heteroconjugate antibodies are composed of two covalently joined antibodies. It is contemplated that the antibodies may be prepared in vitro using known methods in synthetic protein chemistry, including those involving crosslinking agents. For example, one of the antibodies in the heteroconjugate can be coupled to avidin, the other to biotin. Heteroconjugate antibodies may be made using any convenient cross-linking methods. Suitable cross-linking agents and cross-linking techniques are well known in the art.
[0111] Techniques for generating bispecific antibodies from antibody fragments have also been described in the literature. For example, bispecific antibodies can be prepared using chemical linkage.
[0112] Recent progress has facilitated the direct recovery of Fab'-SH fragments from E. coli, which can be chemically coupled to form bispecific antibodies. Various techniques for making and isolating bispecific antibody fragments directly from recombinant cell culture have also been described.
[0113] The term "diabodies" refers to small antibody fragments prepared by constructing scFv fragments with short linkers (about 5 to 10 residues) between the VH and VL domains such that inter chain but not intra chain pairing of the V domains is achieved, resulting in a bivalent fragment, i.e., fragment having two antigen binding sites. Bispecific diabodies are heterodimers of two "crossover" scFv fragments in which the VH and VL domains of the two antibodies are present on different polypeptide chains.
[0114] According to an alternative "diabody" technology for making bispecific antibody fragments, the fragments comprise a VH connected to a VL by a linker which is too short to allow pairing between the two domains on the same chain. Accordingly, the VH and VL domains of one fragment are forced to pair with the complementary VL and VH domains of another fragment, thereby forming two antigen-binding sites. Another strategy for making bispecific antibody fragments by the use of single-chain Fv (scFv) dimers has also been reported.
[0115] Antibodies with more than two valencies are contemplated for use in the invention. For example, trispecific antibodies can be prepared.
[0116] Multivalent Antibodies
[0117] A multivalent antibody may be internalized (and/or catabolized) faster than a bivalent antibody by a cell expressing an antigen to which the antibodies bind. Antibodies that may be used in the present invention can be multivalent antibodies (which are other than of the IgM class) with three or more antigen binding sites (e.g. tetravalent antibodies), which can be readily produced by recombinant expression of nucleic acid encoding the polypeptide chains of the antibody. The multivalent antibody can comprise a dimerization domain and three or more antigen binding sites. A preferred dimerization domain comprises an Fc region or a hinge region. In this scenario, the antibody will comprise an Fc region and three or more antigen binding sites amino-terminal to the Fc region. A preferred multivalent antibody comprises three to about eight, but preferably four, antigen binding sites. The multivalent antibody comprises at least one polypeptide chain (and preferably two polypeptide chains), wherein the polypeptide chain(s) comprise two or more variable domains. For instance, the polypeptide chain(s) may comprise VD1-(X1)n-VD2-(X2)n-Fc, wherein VD 1 is a first variable domain, VD2 is a second variable domain, Fc is one polypeptide chain of an Fc region, Xi and X2 represent an amino acid or polypeptide, and n is 0 or 1. For instance, the polypeptide chain(s) may comprise: VH-CH1-flexible linker-VH-CH1-Fc region chain; or VH-CH1-VH-CH1-Fc region chain. A multivalent antibody preferably further comprises at least two (and preferably four) light chain variable domain polypeptides. A multivalent antibody may, for instance, comprise from about two to about eight light chain variable domain polypeptides. The light chain variable domain polypeptides contemplated here comprise a light chain variable domain and, optionally, further comprise a CL domain.
[0118] Peptide and Peptide Mimetic Inhibitors
[0119] In another embodiment, the inhibitor of VEGF-D activity, VEGFR-3-mediated signaling or lymphangiogenesis is a peptide or peptide mimetic. The peptide or peptide mimetic may reduce receptor availability for native ligand binding.
[0120] As used herein, "peptide mimetic" and "peptidomimetic" are used interchangeably.
[0121] A peptide inhibitor is a peptide that binds specifically to a component of VEGF-C or VEGF-D activity, VEGFR-3-mediated signaling or lymphangiogenesis and inhibits or neutralizes the function of that component in the process of VEGF-C or VEGF-D activity, VEGFR-3-mediated signaling or lymphangiogenesis. Peptide inhibitors may be chemically synthesized using known peptide synthesis methodology or may be prepared and purified using recombinant technology. The preferred length of peptide inhibitors of VEGF-C or VEGF-D activity, VEGFR-3-mediated signaling or lymphangiogenesis is from about 6, 7, 8, 9 or 10 amino acid residues to about 100 amino acid residues. It is contemplated that longer peptides may prove useful. Peptide inhibitors may be identified without undue experimentation using well known techniques. In this regard, it is noted that techniques for screening peptide libraries for peptides that are capable of specifically binding to a polypeptide target are well known in the art.
[0122] For any of the foregoing peptides, one preferred variation involves peptides that have been modified to comprise an intramolecular bond between two non-adjacent amino acid residues of the primary sequence, thereby forming a cyclic peptide. For example, in one variation, the peptide comprises a pair of cysteine residues, such as amino-and carboxy-terminal cysteines, and the intramolecular bond comprises a disulfide bond between the cysteines. However, organic chemists and peptide chemists are capable of synthesizing intramolecular bonds between a wide variety of amino acids using conventional techniques.
[0123] Nucleic Acid Molecules
[0124] Antisense Molecules
[0125] In yet another embodiment, the inhibitor of VEGF-C or VEGF-D activity, VEGFR-3-mediated signaling or lymphangiogenesis is an antisense molecule that reduces transcription and/or translation of a component of VEGF-C or VEGF-D activity, VEGFR-3-mediated signaling or lymphangiogenesis, thereby reducing VEGF-C or VEGF-D activity, VEGFR-3-mediated signaling or lymphangiogenesis.
[0126] The antisense molecule comprises RNA or DNA prepared using antisense technology, where, for example, an antisense RNA or DNA molecule acts to block directly the translation of mRNA by hybridizing to targeted mRNA and preventing protein translation. Binding of antisense or sense oligonucleotides to target nucleic acid sequences results in the formation of duplexes that block transcription or translation of the target sequence by one of several means, including enhanced degradation of the duplexes, premature termination of transcription or translation, or by other means. The antisense oligonucleotides thus may be used to reduce or block expression of a component of VEGF-C or VEGF-D activity, VEGFR-3-ediated signaling or lymphangiogenesis, and thus VEGF-C or VEGF-D activity, VEGFR-3-mediated signaling or lymphangiogenesis. Such oligonucleotides can also be delivered to cells such that the antisense RNA or DNA may be expressed in vivo to inhibit production of components of VEGF-C or VEGF-D activity, VEGFR-3-mediated signaling or lymphangiogenesis.
[0127] Inhibitors of VEGF-C or VEGF-D activity or signaling mediated by VEGFR-3, or lymphangiogenesis include antisense or sense oligonucleotides comprising a single-stranded nucleic acid sequence (either RNA or DNA) capable of binding to target mRNA (sense) or DNA (antisense) sequences. Such a fragment generally comprises about 10 to 40 nucleotides in length, preferably at least about 14 nucleotides, preferably from about 14 to 30 nucleotides.
[0128] Antisense or sense oligonucleotides further comprise oligonucleotides having modified sugar-phosphodiester backbones that are resistant to endogenous nucleases, or are covalently linked to other moieties that increases affinity of the oligonucleotide for a target nucleic acid sequence, or intercalating agents to modify binding specificities of the antisense or sense oligonucleotide for the target nucleotide sequence.
[0129] Small Interfering RNA (siRNA)
[0130] In one embodiment, it is envisaged that siRNA will inhibit VEGF-C or VEGF-D activity, VEGFR-3-mediated signaling or lymphangiogenesis. "siRNA" or "RNAi" are double-stranded RNA molecules, typically about 21 nucleotides in length, that are homologous to a gene or polynucleotide that encodes the target gene and interfere with the target gene's expression.
[0131] Nucleic Acid Molecules in Triple-Helix Formation
[0132] In another embodiment, the inhibitor of VEGF-C or VEGF-D activity, VEGFR-3-mediated signaling or lymphangiogenesis comprises nucleic acid molecules in triple-helix formation. Nucleic acid molecules in triple-helix formation used to inhibit transcription should be single-stranded and composed of deoxynucleotides. A DNA oligonucleotide is designed to be complementary to a region of the gene involved in transcription. The base composition of these oligonucleotides is designed such that it promotes triple-helix formation via Hoogsteen base-pairing rules, which generally require sizeable stretches of purines or pyrimidines on one strand of a duplex.
[0133] Ribozymes
[0134] In a related embodiment, the inhibitor of VEGF-C or VEGF-D activity, VEGFR-3-mediated signaling or lymphangiogenesis is a ribozyme that reduces transcription of a component of VEGF-C or VEGF-D activity or signaling mediated by VEGFR-3, or a lymphangiogenic component.
[0135] A "ribozyme" is an enzymatic RNA molecule capable of catalyzing the specific cleavage of RNA. Ribozymes act by sequence-specific hybridization to the complementary target RNA, followed by endonucleolytic cleavage. Specific ribozyme cleavage sites within a potential RNA target can be identified by known techniques.
[0136] Small Molecule Inhibitors
[0137] In a further embodiment, the inhibitor of VEGF-C or VEGF-D activity, VEGFR-3-mediated signaling or lymphangiogenesis is a small molecule.
[0138] A "small molecule" is defined herein to have a molecular weight below about 2000 daltons, and preferably below about 500 Daltons. Potential inhibitors of VEGF-C or VEGF-D activity, VEGFR-3-mediated signaling or lymphangiogenesis include small molecules that bind to the active site, the receptor binding site, or growth factor or other relevant binding site of components of VEGF-C or VEGF-D activity or VEGFR-3-mediated signaling, or lymphangiogenesis, thereby blocking the normal biological activity of VEGF-C or VEGF-D, VEGFR-3-mediated signaling or lymphangiogenesis. Examples of small molecules include, but are not limited to, synthetic non-peptidyl organic or inorganic compounds.
[0139] Small molecule inhibitors of VEGF-C or VEGF-D activity, VEGFR-3-mediated signaling or lymphangiogenesis may be identified without undue experimentation using known techniques and chemically synthesized using known methodology. In this regard, it is noted that techniques for screening organic molecule libraries for molecules that are capable of binding to a polypeptide target are known in the art.
[0140] Inhibition of Receptor Availability for Ligand Binding
[0141] Antibody Inhibitors
[0142] In one embodiment, the inhibitor of VEGF-C or VEGF-D activity, VEGFR-3-mediated signaling or lymphangiogenesis is an antibody. In a preferred embodiment, the inhibitor of VEGF-C or VEGF-D activity, VEGFR-3-mediated signaling or lymphangiogenesis is an anti-VEGFR-3 antibody that reduces VEGFR-3 availability for ligand binding.
[0143] Suitable antibodies for use in the methods of the invention and means for their production are disclosed in WO2000/021560 and WO1995/021868 and include a polyclonal or a monoclonal antibody that binds specifically to VEGFR-3 and blocks its signaling, a fragment of such an antibody, a chimeric antibody, a humanized antibody, and a bispecific antibody that binds specifically to VEGFR-3 and blocks its signaling and also binds to another antigen.
[0144] In a preferred embodiment, the antibody inhibitor is a humanized antibody. In another embodiment, the antibody inhibitor of VEGF-C or VEGF-D activity, VEGFR-3-mediated signaling or lymphangiogenesis comprises a Fab, Fab', or F(ab')2 fragment, or a single chain Fv (scFv) fragment.
[0145] Persons skilled in the art will appreciate that in particular embodiments, the monoclonal antibody may comprise antibody 9D9F9, disclosed in WO2000/021560 or 2E11D11 disclosed in WO2003/006104. Alternatively monoclonal antibodies that specifically bind to VEGFR-3 and may be used according to the invention include antibodies MM0003-7G63, RM0003-5F63, C28G5, KLT9, ZMD.251, mF4-31C1 and hF4-3C5. A particularly preferred monoclonal antibody is hF4-3C5, a fully-humanized antagonist antibody to human VEGFR-3.
[0146] In an alternative embodiment, the inhibitor may comprise a bispecific antibody, particularly a diabody, that binds specifically to and neutralizes each of VEGFR-3 and a second target. One example of such a diabody is that derived from antibodies hF4-3C5 and IMC-1121, which binds specifically to and neutralizes each of VEGFR-3 and VEGFR-2.
[0147] An inhibitor of VEGF-C or VEGF-D activity, VEGFR-3-mediated signaling or lymphangiogenesis according to the present invention also includes in one embodiment an antibody, as described above, that inhibits or neutralizes the receptor tyrosine kinase activity of VEGFR-3.
[0148] Peptide and Peptide Mimetic Inhibitors
[0149] The person skilled in the art will appreciate that particular inhibitors of VEFD-C or VEGF-D activity, VEGFR-3-mediated signaling or lymphangiogenesis that can be employed in a particular embodiment of the present invention are disclosed in WO2000/021560, WO2001/052875, and WO2002/057299, which are incorporated herein by reference. In one embodiment, the inhibitor of VEGF-C or VEGF-D activity, VEGFR-3-mediated signaling or lymphangiogenesis comprises a peptide. Such a peptide to be used as an inhibitor of VEFC-C or VEGF-D activity, VEGFR-3-mediated signaling or lymphangiogenesis can be generated by random peptide synthesis, by recombinant means from random oligonucleotides, or a peptide may be selected from a phage display library, according to the disclosure of WO2002/057299 and WO2000/021560 and methods standard in the art. Such a peptide can be identified with the aid of the VEGFR-3 extracellular domain.
[0150] In a particular embodiment, the peptide inhibitor of VEGF-C or VEGF-D activity, VEGFR-3-mediated signaling or lymphangiogenesis comprises the amino acid sequence GYWX1X2X3W (SEQ ID NO: 32), wherein Xi, X2, and X3 comprise amino acids and wherein the peptide binds VEGFR-3, according to WO2002/057299. In a related embodiment, the peptide inhibitor comprises the amino acid sequence GYWX1X2X3WX4 (SEQ ID NO: 33), wherein X4 comprises an amino acid. In another embodiment, either of the preceding peptides may further comprise an amino- and carboxy-terminus cysteine residue. In a particular embodiment, the peptide comprises a cyclic peptide. In an alternative embodiment, the peptide comprises a peptide dimer that binds to VEGFR-3, and in a preferred form, the peptides comprising the dimer are the same, according to WO2002/057299.
[0151] In one embodiment, the peptidomimetic inhibitor is a monomeric monocyclic peptide inhibitor or dimeric bicyclic peptide inhibitor. Preferably, such peptidomimetic inhibitors are based on the peptide sequence of exposed loops of growth factor proteins, for example, loops 1, 2, and 3 of VEGF-D. In a preferred embodiment, the peptidomimetic inhibitor comprises any one of: CASELGKSTNTFC (SEQ ID NO: 42); CNEESLIC (SEQ ID NO: 43); or CISVPLTSVPC (SEQ ID NO: 44).
[0152] In one embodiment, the peptide mimetic inhibitor is prepared by the methods disclosed in WO2001/052875 and WO2002/057299. Peptides that may be used as inhibitors of VEGF-D activity, VEGFR-3-mediated signaling or lymphangiogenesis are disclosed in WO2000/021560. Such peptides include a polypeptide comprising a fragment or analog of a vertebrate VEGF-C polypeptide, wherein the polypeptide and fragment or analog are capable of binding to VEGFR-3, but do not activate signaling, and a polypeptide comprising a fragment or analog of a vertebrate VEGF-C or VEGF-D polypeptide, wherein the polypeptide and fragment or analog are capable of binding to VEGFR-3, but do not activate signaling.
[0153] The person skilled in the art will appreciate that inhibitors of VEGF-D activity, VEGFR-3-mediated signaling or lymphangiogenesis inhibitors according to WO2002/057299 include peptides comprising the sequence YIGYWLTIWGY2, wherein Y, and Y2 are amino acids. In one variation, the peptide is made cyclic by a bond between Y and Y2. In a specific preferred embodiment, the peptide comprises the sequence CGYWLTIWGC (SEQ ID NO: 42). Other peptide inhibitors comprise any of the following amino acid sequences: SGYWWDTWF (SEQ ID NO: 1), SCYWRDTWF(SEQ ID NO: 2), KVGWSSPDW (SEQ ID NO: 3), FVGWTKVLG (SEQ ID NO: 4), YSSSMRWRH (SEQ ID NO: 5), RWRGNAYPG (SEQ ID NO: 6), SAVFRGRWL (SEQ ID NO: 7), WFSASLRFR (SEQ ID NO: 8), WQLGRNWI (SEQ ID NO: 9), VEVQITQE (SEQ ID NO: 10), AGKASSLW (SEQ ID NO: 11), RALDSALA (SEQ ID NO: 12), YGFEAAW (SEQ ID NO: 13), YGFLWGM (SEQ ID NO: 14), SRWRILG (SEQ ID NO: 15), HKWQKRQ (SEQ ID NO: 16), MDPWGGW (SEQ ID NO: 17), RKVWDIR (SEQ ID NO: 18), VWDHGV (SEQ ID NO: 19), CWQLGRNWIC (SEQ ID NO: 20), CVEVQITQEC (SEQ ID NO: 21), CAGKASSLWC (SEQ ID NO: 22), CRALDSALAC (SEQ ID NO: 23), CYGFEAAWC (SEQ ID NO: 24), CYGFLWGMC (SEQ ID NO: 25), CSRWRILGC (SEQ ID NO: 26), CHKWQKRQC (SEQ ID NO: 27), CMDPWGGWC (SEQ ID NO: 28), CRKVWDIRC (SEQ ID NO: 29), CVWDHGVC (SEQ ID NO: 30), CGQMCTVWCSSGC (SEQ ID NO: 31), or conservative substitutions-variants thereof. Preferred peptides comprise these exact amino acid sequences, or sequences in which only one or only two conserved substitutions have been introduced. In another preferred variation, the peptides comprise amino-and carboxy-terminal cysteines, which permit formation of cyclic molecules and dimers and multimers. In yet another variation, peptide inhibitors include the amino acid sequence GYWXIX2X3W (SEQ ID NO: 32), wherein X, X2, and X3 comprise amino acids, the amino acid sequence GYWX, XZX3WX4 (SEQ ID NO: 33), wherein X4 comprises an amino acid. In still another variation, these peptides further comprise amino-and carboxy-terminal cysteine residues.
[0154] Nucleic Acid Inhibitors
[0155] In a preferred embodiment, the invention envisages use of a VEGFR-3 antisense RNA, as disclosed in WO2000/021560, to inhibit the translation of VEGFR-3-encoding mRNA to eliminate or downregulate levels of VEGFR-3. Similarly, siRNA or nucleic acids in triple helix formation could be used to reduce VEGFR-3 availability for ligand binding.
[0156] Small Molecule Inhibitors
[0157] In a preferred embodiment, the small molecule is a small molecule inhibitor of receptor tyrosine kinase activity. In a more preferred embodiment, the small molecule comprises PTK787/ZK22854, AZP2171, ZK991, KRN633, MAZ51, sorafenib, sunitinib (SU11248), axitinib (AG013736), vandetanib (ZD6474), or 3-(indole-3-yl)-4-(3,4,5-trimethoxyphenyl)-1H-pyrrole-2,5-dione.
[0158] Inhibition of Ligand Availability for Receptor Binding
[0159] Antibody Inhibitors
[0160] According to one embodiment, inhibition of VEGF-C or VEGF-D activity, VEGFR-3-mediated signaling or lymphangiogenesis can be achieved using antibodies that specifically bind and neutralize ligands for VEGFR-3, that is, VEGF-C and/or VEGF-D. Antibodies similar to anti-VEGFR-3 antibodies described above are contemplated. Suitable antibodies and their means for production are disclosed in WO2000/021560. The person skilled in the art will appreciate that antibodies that bind specifically to VEGF-D and may be used according to the invention include monoclonal antibodies 2F8, 4A5 (also known as VD1), 4E10, 5F12, 4H4 and 3C10 disclosed in WO2000/037025. A particularly preferred antibody is 4A5, and in particular, a humanized version thereof. In another embodiment, the chimeric or humanized antibody comprises SEQ ID NO: 46 and SEQ ID NO: 47, or the antibody comprises any one of SEQ ID NOs: 48 to 50 and any one of SEQ ID NOs: 51 to 53, as disclosed in WO2005/087177. Alternatively monoclonal antibodies that may be used according to the invention include 28AT743.288.48, MM0007-7E79, RM0007-8C35, 78902, 78923, 78939, and 90409.
[0161] Similarly, monoclonal antibodies that bind VEGF-C may be employed. The anti-VEGF-C antibodies will specifically bind to human VEGF-C or a biologically active fragment thereof, e.g. the mature fully-processed form. Such binding will partially or fully block, neutralize, reduce or antagonize VEGF-C activity. Suitable examples of such antibodies include antibodies 103, MM0006-2E65 and 193208. Further examples of such antibodies are found in US 7,208,582 and US 7,109,308.
[0162] One example of an anti-VEGF-C antibody is a monoclonal antibody that competitively inhibits the binding to VEGF-C of monoclonal anti-VEGF-C antibody 69D09 produced by hybridoma ATCC PTA-4095 or having the heavy and light chain amino acid sequences as follows:
TABLE-US-00001 SEQ ID NO: 34 EVRLLESGGG LVQPGGSLRL SCAASGFTFR PRAMAWVRQA 10 20 30 40 PGKGLEWVSS ISAQGASAYY ADSVKGRFTI SRDNSKNTLY 50 60 70 80 LQMNSLRAED TAVYYCARDL SVSGFGPWGR GTMVTVSSAS 90 100 110 120 TKGPSVFPLA PSSKSTSGGT AALGCLVKDY FPEPVTVSWN 130 140 150 160 SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSSLGTQTYI 170 180 190 200 CNVNHKPSNT KVDKRVEPKS CDKTHTCPPC PAPELLGGPS 210 220 230 240 VFLFPPKPKD TLMISRTPEV TCVVVDVSHE DPEVKFNWYV 250 260 270 280 DGVEVHNAKT KPREEQYNST YRVVSVLTVL HQDWLNGKEY 290 300 310 320 KCKVSNKALP APIEKTISKA KGQPREPQVY TLPPSREEMT 330 340 350 360 KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD 370 380 390 400 SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH EALHNHYTQK 410 420 430 440 SLSLSPGK 448
[0163] Sequence of Anti-VEGF-C Antibody Heavy Chain
TABLE-US-00002 SEQ ID NO: 35 SYELTQPPSS SGTPGQRVTI SCSGSSSNIG RHTVSWYQQV 10 20 30 40 PGTAPKLLIY SDDHRPSGVP DRFSASKSGT SASLTITGLQ 50 60 70 80 SEDEADYYCA AWDDSLNGPW VFGGGTKLTV LGQPKAAPSV 90 100 110 120 TLFPPSSEEL QANKATLVCL ISDFYPGAVT VAWKADSSPV 130 140 150 160 KAGVETTTPS KQSNNKYAAS SYLSLTPEQW KSHRSYSCQV 170 180 190 200 THEGSTVEKT VAPTECS 210 217
Sequence of Anti-VEGF-C Antibody Light Chain
[0164] Another example of an anti-VEGF-C antibody is a monoclonal antibody that binds to the same epitope as the monoclonal anti-VEGF-C antibody 69D09 produced by hybridoma ATCC PTA-4095 or a monoclonal antibody having the heavy and light chain amino acid sequences shown above. In one embodiment, the anti-VEGF-C antibody is a fully-human anti-VEGF-C monoclonal antibody, including but not limited to 69D09 antibody or fragment thereof. The anti-VEGF-C antibody may be a humanized antibody.
[0165] Preferably, the anti-VEGF-C antibody is a human antibody produced by deposited hybridoma ATC PTA-4095 (also referred to herein as "VGX-100") or having the heavy and light chain amino acid sequences shown above.
[0166] Alternatively, antibodies may bind proprotein convertases, enzymes responsible for processing VEGF-C and VEGF-D from their prepro-forms to their activated forms, and reduce, inhibit or neutralize such activity thereby limiting the amount of proteolytically processed ligand available for binding to VEGFR-3. Again, antibodies corresponding with anti-VEGFR-3 antibodies described above are envisaged. Such antibodies are disclosed in WO05/112971 and include neutralizing antibodies to inhibit the biological action of proprotein convertases.
[0167] Peptide Inhibitors
[0168] Inhibitors of VEGF-C or VEGF-D activity, VEGFR-3-mediated signaling or lymphangiogenesis as used in the present invention include inhibitors of proprotein convertases. As noted, one class of inhibitor of proprotein convertases comprises antibodies. Another class of inhibitor of proprotein convertases includes peptide inhibitors.
[0169] Peptide inhibitors of proprotein convertases are disclosed in WO05/112971 and include prosegments of proprotein convertases, inhibitory variants of anti-trypsin and peptidyl haloalkylketone inhibitors.
[0170] Representative inhibitory prosegments of proprotein convertases include the inhibitory prosegments of PC5A (also known as PC6A), PC5B (also known as PC6B), PACE4, PC1 (also known as PC3), PC2, PC4, PC7 and Furin. A representative inhibitory variant of anti-trypsin is a-1 antitrypsin Portland, an engineered variant of naturally occurring antitrypsin that inhibits multiple proprotein convertases. Representative peptidyl halomethyl ketone inhibitors include decanoyl-Arg-Val-Lys-Arg-chloromethylketone (Dec-RVKR-CMK), decanoyl-Phe-Ala-Lys-Arg-chloromethylketone (Dec-FAKR-CMK), decanoyl-Arg-Glu-Ile-Arg-chloromethylketone (Dec-REIR-CMK), and decanoyl-Arg-Glu-Lys-Arg-chloromethylketone (Dec-REKR-CMK). These inhibitors of proprotein convertases, such as Dec-RVKR-CMK or the inhibitory prosegments of proprotein convertases, can be used to block the activation of VEGF-C and VEGF-D and thereby inhibit VEGF-C or VEGF-D activity, VEGFR-3-mediated signaling or lymphangiogenesis induced by partially processed or fully processed VEGF-C or VEGF-D.
[0171] Soluble Receptors
[0172] According to another embodiment, VEGF-C or VEGF-D activity, VEGFR-3-mediated signaling or lymphangiogenesis can be inhibited using soluble receptors that bind VEGFR-3 ligands. Soluble receptors capable of binding VEGF-C and VEGF-D, thereby inhibiting VEGF-C or VEGF-D activity or signaling via VEGFR-3, are disclosed in WO2000/023565, WO2000/021560 and WO2002/060950. Such inhibitors of VEGF-D activity, VEGFR-3-mediated signaling or lymphangiogenesis inhibitors include soluble VEGFR-2, VEGFR-3, NRP-1, and NRP-2.
[0173] Nucleic Acid Inhibitors
[0174] In another embodiment of the invention, antisense oligonucleotides are used as inhibitors of proprotein convertases. The antisense oligonucleotides preferably inhibit expression of proprotein convertases by inhibiting transcription or translation of proprotein convertases. In a further embodiment, the antagonizing agent is small interfering RNAs (siRNA, also known as RNAi, RNA interference nucleic acids). Also contemplated are methods of inhibiting the target gene expression or target protein function utilizing ribozymes and triplex-forming nucleic acid molecules.
[0175] Similarly, in a related embodiment, antisense, siRNA and ribozyme inhibitors directed to VEGF-C and/or VEGF-D are included as inhibitors of VEGF-C or VEGF-D activity, VEGFR-3-mediated signaling or lymphangiogenesis exerting their effects by reducing transcription and/or translation of VEGF-C and VEGF-D.
[0176] Peptide and Peptide Mimetic Inhibitors
[0177] According to one embodiment, the inhibitor to be used in the invention comprises a peptide that reduces the availability of ligand to bind to VEGFR-3. Such a peptide can be generated by random peptide synthesis, by recombinant means from random oligonucleotides, or a peptide may be selected from a phage display library by methods standard in the art. In a particular embodiment, the peptide will be derived from VEGFR-3 or VEGFR-2 and will bind specifically to VEGF-C or VEGF-D such that the ligand available for binding to native VEGFR-3 is reduced. Such a peptide may be identified with the aid of the VEGF-C or VEGF-D.
[0178] Small Molecule Inhibitors
[0179] In one embodiment, the small molecule inhibitor is a small molecule inhibitor of a proprotein convertase. In a particular embodiment, the proprotein convertase is furin and the small molecule comprises B3 (CCG8294, naphthofluorescein disodium) or a derivative of 2,5-dideoxystreptamine.
[0180] Antibody Inhibitors Affecting Ligand--Receptor Complex
[0181] In one embodiment, the invention includes use of bispecific antibodies, as described above, as inhibitors of VEGF-C or VEGF-D activity, VEGFR-3-mediated signaling or lymphangiogenesis, specifically inhibiting ligand-receptor complexes.
[0182] Suitable antibodies and their means for production are disclosed in WO2000/021560 and include a bispecific antibody that binds specifically to an epitope or epitopes derived from a VEGFR-3-(VEGFR-3 ligand) complex (receptor-ligand complex) and blocks VEGFR-3 signaling.
[0183] Inhibition of Co-Receptor Interaction
[0184] Antibody Inhibitors Affecting Co-Receptors of VEGFR-3
[0185] In a further embodiment, inhibitors of VEGF-C or VEGF-D activity, VEGFR-3-mediated signaling or lymphangiogenesis include antibodies, as described above, that bind specifically to and reduce, inhibit or neutralize co-receptor binding to VEGFR-3. Such antibodies may be directed to a co-receptor, a ligand-co-receptor binary complex, a co-receptor-receptor binary complex, or a ligand-co-receptor-receptor ternary complex. Co-receptors include NRP-1 and NRP-2. The person skilled in the art will understand that monoclonal antibodies that specifically bind NRP-1 or NRP-2 and may be used according to the invention include antibodies 1B3, 3G6-2C5, AD5-17F6, 446915, 446921, 130603, 130604, 96009, 3B8, 54, 257103, 257107, A-12, and C-9. Alternatively, a bispecific antibody which specifically binds to NRP-2 receptor and a VEGF-C polypeptide, as disclosed in WO2003/029814, may be used according to the invention.
[0186] Peptide Inhibitors Affecting Co-Receptors of VEGFR-3
[0187] In another embodiment, a peptide inhibitor comprising a peptide dimer may target one or more receptors and/or co-receptors. Co-receptors include NRP-1 and NRP-2. As disclosed in WO2002/057299, in a particular embodiment, the peptide dimer comprises one peptide that binds VEGFR-3 and a second peptide that binds to any one of VEGFR-1, VEGFR-2, NRP-1, or NRP-2.
[0188] Small Molecule and Nucleic Acid Inhibitors Affecting Co-Receptors of VEGFR-3
[0189] According to the present invention, it is also envisaged that small molecules, antisense molecules, siRNA and ribozymes, as described above, can be utilized as inhibitors of VEGF-D activity, VEGFR-3-mediated signaling or lymphangiogenesis by targeting co-receptors that interact with VEGFR-3. Such co-receptors include NRP-1 and NRP-2.
[0190] Inhibition of Downstream Signaling
[0191] Alternatively, an inhibitor of VEGF-C or VEGF-D activity, VEGFR-3-mediated signaling or lymphangiogenesis according to any of the foregoing descriptions may disrupt downstream intracellular VEGFR-3 signaling, as disclosed in WO2000/021560.
Pharmaceutically Acceptable Carriers
[0192] Suitable ophthalmic carriers are known to those skilled in the art and all such conventional carriers may be employed in the present invention. Exemplary compounds incorporated to facilitate and expedite transdermal delivery of topical compositions into ocular or adnexal tissues include, but are not limited to, alcohol (ethanol, propanol, and nonanol), fatty alcohol (lauryl alcohol), fatty acid (valeric acid, caproic acid and capric acid), fatty acid ester (isopropyl myristate and isopropyl n-hexanoate), alkyl ester (ethyl acetate and butyl acetate), polyol (propylene glycol, propanedione and hexanetriol), sulfoxide (dimethylsulfoxide and decylmethylsulfoxide), amide (urea, dimethylacetamide and pyrrolidone derivatives), surfactant (sodium lauryl sulfate, cetyltrimethylannmonium bromide, polaxamers, spans, tweens, bile salts and lecithin), terpene (d-limonene, alphaterpeneol, 1,8-cineole and menthone), and alkanone (N-heptane and N-nonane). Moreover, topically-administered compositions comprise surface adhesion molecule modulating agents including, but not limited to, a cadherin antagonist, a selectin antagonist, and an integrin antagonist. Thus, a particular carrier may take the form of a sterile, ophthalmic ointment, cream, gel, solution, or dispersion. Also including as suitable ophthalmic carriers are slow release polymers, e.g., "Ocusert" polymers, "Hydron" polymers, etc.
[0193] Stabilizers may also be used such as, for example, chelating agents, e.g., EDTA. Antioxidants may also be used, e.g., sodium bisulfite, sodium thiosulfite, 8-hydroxy quinoline or ascorbic acid. Sterility typically will be maintained by conventional ophthalmic preservatives, e.g., chiorbutanol, benzalkonium chloride, cetylpyridium chloride, phenyl mercuric salts, thimerosal, etc., for aqueous formulations, and used in amounts which are nontoxic and which generally vary from about 0.001 to about 0.1% by weight of the aqueous solution. Conventional preservatives for ointments include methyl and propyl parabens. Typical ointment bases include white petrolatum and mineral oil or liquid petrolatum. However, preserved aqueous carriers are preferred. Solutions may be manually delivered to the eye in suitable dosage form, e.g., eye drops, or delivered by suitable microdrop or spray apparatus typically affording a metered dose of medicament. Examples of suitable ophthalmic carriers include sterile, substantially isotonic, aqueous solutions containing minor amounts, i.e., less than about 5% by weight hydroxypropylmethylcellulose, polyvinyl alcohol, carboxymethylcellulose, hydroxyethylcelullose, glycerine and EDTA. The solutions are preferably maintained at substantially neutral pH and isotonic with appropriate amounts of conventional buffers, e.g., phosphate, borate, acetate, tris.
[0194] All publications and patents mentioned herein are hereby incorporated by reference in their entirety as if each individual publication or patent was specifically and individually indicated to be incorporated by reference. In case of conflict, the present application, including any definitions herein, will control.
EXAMPLES
Materials and Methods
Experimental Dry Eye Murine Model
[0195] Eight to ten week-old female C57BLI6 mice (Charles River Laboratory, Wilmington, Mass.) were used in accordance with the standards in the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. The research protocol was approved by the Schepens Eye Research Institute Animal Care and Use Committee. Dry eye was induced in murine eyes using a Controlled Environment Chamber (CEC) which exposes the mice to high-flow desiccated air. To achieve maximum ocular surface dryness, the conditions in CEC were supplemented with topical application of 1% atropine sulfate (Falcon Pharma, Fort Worth, Texas) twice for the first 48 hours and subcutaneous injections of 0.1 ml of 5 mg/ml of scopolamine hydrobromide (Sigma-Aldrich, St. Louis, Mo.) three times a day, for the entire duration of the experiment.
RNA Isolation and Molecular analysis using Real Time Polymerase Chain Reaction
[0196] Five mice (10 eyes) were included in each group. Two corneas were pooled together to equal as one sample and stored at -80°C in Trizol (Invitrogen, Carlsbad, Calif.; catalog No.15596026) until future use. Total RNA was isolated from these corneas using the RNeasy microkit (Qiagen, Valencia, Calif.; catalog No. 74004). Equal amounts of RNA were used to synthesize cDNA using SuperScript® III Reverse Trancriptase (Invitrogen, Carlsbad, Calif.; catalog No.18080) according to the manufacturer's recommendations. Real-Time PCR was performed using FAM-MGB dye labeled predesigned primers (Applied Biosystem, Foster City, Calif.) for GAPDH (assay ID.Mm999999 15_gl), VEGF-A (Mm00437304_ml), VEGF-C (Mrn00437313_ml), VEGF-D (Mm00438965_ml), VEGFR-2 (Mm00440099_ml), VEGFR-3 (Mm00433337_ml). 2.5 μl of cDNA was loaded in each well and assays were performed in duplicate. The GAPDH gene was used as the endogenous reference for each reaction. The results were normalized by the cycle threshold (CT) of GAPDH and the relative mRNA level in the normal mice was used as the normalized control.
Immunohistochemistry
[0197] The following primary antibodies were used for immunohistochemical staining: rat anti-mouse CD11b-FITC for monocytes/macrophages (BD Pharmingen, San Diego, Calif., 1:100), goat anti-mouse CD31 FITC as pan-endothelial marker (Santa Cruz Biotechnology, Santa Cruz, Calif., 1: 100) and purified rabbit anti-mouse LYVE-1 as iymphatic endothelial marker (Abeam, Mass., USA, 1:400). Respective isotypes were used as negative controls.Rhodamine conjugated goat anti-rabbit (BD Pharmingen, San Diego, Calif., 1:100) was the secondary antibody used.
[0198] Freshly excised corneas were washed in PBS, fixed in acetone for 15 minutes and then double stained with CD31 and LYVE-1 as described previously. To analyze infiltration of CD11b.sup.+/LYVE-1 cells, corneas from three mice from each group were taken and cells were counted in 5-6 areas in the periphery (0.5 μm area from the limbus) of each cornea in a masked fashion, using epifluorescence microscope (model E800; Nikon, Melville, NY) at 40X magnification. The mean number of cells was obtained by averaging the total number of cells in all the areas studied and the result was expressed as the number of positive cells per mm2.
Morphometry of Lymphangiogenesis in the Cornea
[0199] Morphology of lymphatics was analyzed using an automated image analysis program written with Matlab (The Mathworks, Inc., Natick, Mass.). Lymphatics were isolated from digitized images with this program using standard computer vision techniques for image segmentation, including background isolation and subtraction, edge detection, and k-means clustering. This segmentation process generated binary images in which lymphatic vessels are represented by 1s and all other image content is represented by Os. The resultant isolated lymphatic vessels were analyzed morphologically using two metrices, Lymphatic Area (LA) and Lymphatic Caliber (LC). LA represents the total surface area of the lymphatic vessels when projected into the plane of the image. LC is a summary measure of the diameters of the lymphatic vessels present. LC was measured using a computational technique that generates the largest diameter circle centered at each pixel inside a lymphatic vessel. The mean value across all pixels within lymphatic vessels was taken as an estimate of the mean LC for a given image.
Flow Cytometry
[0200] Draining LNs from DED (day 10) and normal mice were collected. Single cell suspension of LN cells was stained with the anti-CDI lb-FITC and anti-lab (MHC-II)-PE. Stained LN cells were then analyzed on an EPICS XL flow cytometer (Beckman Coulter). All the antibodies with their matched isotype controls were purchased from eBioscience.
Studies Involving Inhibition of Corneal Neo-Lymphangiogenesis using an Anti-VEGF-C Antibody (Example 5 Onwards)
[0201] Anti-VEGF-C antibodies (VGX-100; Vegenics Limited, Australia) were administered intraperitonealy daily from day 1 to day 10 to DED mice. Mice were assessed clinically using corneal fluorescent staining. Tissues from cornea, conjunctiva and draining lymph nodes were examined for cellular and molecular pathological changes. In vivo blockade of VEGF-C suppresses corneallymphangiogenesis and ameliorates clinical signs of DED.
Statistical Analysis
[0202] A two-tailed Student's t-test was performed and P-values less than 0.05 were deemed statistically significant. Results are presented as the mean±SEM of at least three experiments.
Example 1
Demonstration and Quantification of Lymphatics in Dry Eye Corneas
[0203] To determine whether DED induces growth of lymphatics into the cornea, and whether lymphatic growth is paralleled by growth of blood vessels, corneal whole mounts were double stained for CD31 (pan-endothelial marker) and LYVE-1 (lymphatic vascular endothelial marker) at days 0, 6, 10 and 14 and quantified for lymphangiogenesis. Blood vessels were identified as CD31hi/LYVE-1.sup.- and lymph vessels were identified as CD31lo/LYVE-1hi. A significant increase in lymphatic area LA is seen in DED mice (FIG. 1b). Morphometric analysis revealed small buds of lymphatic vessels arising from the limbal vascular arcade at an early time point (day 6), which increased in caliber (LC) and area (LA), and advanced towards the center of the cornea with DED progression (FIGS. 1 and 2). A significant increase in LA (FIG. 3a) was seen as early as day 6 (P<0.01) which continued until day 14 (P<0.0001). However, LC (FIG. 3b) was significantly increased from the normal only by day 14 (P<0.02). Remarkably, these lymphatics were not accompanied by growth of blood vessels at any given time point.
Example 2
Expression Levels of Different VEGF's and VEGFR's in Dry Eye Corneas
[0204] The development of lymphatic vessels is regulated by factors common to both hemangiogenesis and lymphangiogenesis. VEGF-C and VEGF-D are the classic lymphangiogenic factors and act by binding to their receptors VEGFR-2 and VEGFR-3, which are expressed on lymphatic endothelial cells. To determine the molecular mechanisms of lymphangiogenesis in DED, expression of different vascular endothelial growth factors and their receptors were quantified at indicated time points in the cornea using real time PCR. Amongst the VEGF species (FIG. 4), lymphangiogenic specific VEGF-D was not only the earliest to increase at day 6 (-2 folds; P<0.03) but also showed the maximum increase in expression at day 14 (-3 folds; P<0.03). Significant increased transcript expression of VEGF-A and VEGF-C was seen only by day 14 (P<0.03 for both). Similarly levels of lymphangiogenic specific VEGFR-3 were first to show a significant increase at day 6 (-4 folds; P<0.01) and continued to rise until day 14 (-8 folds; P<0.01). Though an overall trend toward increased expression was noticed with VEGFR-2 (primarily specific for blood vessel growth), significant increase (P<0.05) was appreciated only by day 14 (FIG. 5).
Example 3
Enumeration of CD11b/LYVE-1 Positive Cells in Dry Eye Corneas
[0205] The normal cornea has a resident population of bone marrow-derived CD11b.sup.+ monocyticmacrophage-lineage cells and the development of DED increases the number of CD11b.sup.+ cells in the cornea. The role of macrophages in inflammatory lymphangiogenesis is well established. These CD11b.sup.+ macrophages may also express various lymphatic endothelial markers, such as LYVE-1. To see what proportion of these CD11b.sup.+ cells had lymphangiogenic potential, whole mount corneal tissues were double stained with CD 11b and LYVE-1 at day 14. There was a significant increase in the number of both CD11b+ (P<0.02) and CD11b.sup.+/LYVE-1.sup.+ (P<0.0001) cells in dry eye as compared to normal corneas (FIG. 6). In DED, about 25% of the CD11b.sup.+ cells were positive for LYVE-1 where as only 4% of the CD11b.sup.+ cells were positive for LYVE-1 in the normal corneas.
Example 4
Role of APC Homing
[0206] It was next investigated whether corneal lymphangiogenesis in DED is associated with the increased homing of APC in the draining LN. Using flow cytometry, the frequencies of mature APC (MHC-II+CD11b+) in the draining LN of normal and DED mice were analysed (FIG. 7). Data showed a significant increase in the frequency of MHC-II+CD11b.sup.+ APC in the LN cells of DED mice compared to those in the LN of normal mice (Range: 14.9-19.5% vs. 10-13.5%, p<0.05).
Example 5
Effect of in vivo Blockade of Pro-Lymphangiogenesic VEGF-C on Dry Eye Disease
[0207] Dry eye was induced in murine eyes as described in the materials and methods.
[0208] Real time PCR was performed to quantify expression of different VEGF growth factors (VEGF-A, VEGF-C, VEGF-D) and their receptors (VEGFR-2, VEGFR-3) in the cornea at days 6, 10 and 14 (FIG. 8) and to determine the levels of proinflammatory cytokines. IL-la, IL-10, IL-6, IL-17 in the conjunctiva showed significantly decreased expression in anti-VEGF-C treated DED mice as compared to those of untreated DED mice (FIG. 9). Draining lymph nodes of anti-VEGF-C treated DED mice showed significantly decreased induction of T-cell mediated autoimmune response compared untreated DED mice as determined by Real-time PCR analysis for IL-17 (Th17 cells) and IFN-γ (Th1 cells) (FIG. 10).
[0209] Enumeration of CD11b.sup.+/LYVE-1.sup.+ monocytic cells was done in the DED corneas at day 14 as described previously (FIGS. 11). Treatment with anti-VEGF-C antibodies significantly decreased infiltration of CD11b.sup.+ cells (30%) in the DED corneas.
[0210] To determine whether DED induces growth of lymphatics into the cornea, and whether lymphatic growth is paralleled by growth of blood vessels, corneal whole mounts were double stained for CD31 (pan-endothelial marker) and LYVE-1 (lymphatic vascular endothelial marker) at days 0, 6, 10 and 14 and quantified for lymphangiogenesis as described previously. Lymphatics were seen growing toward the center of DED corneas (FIG. 12). Morphometric analysis showed significant increase in both lymphatic area (P<0.0001) and lymphatic caliber (P<0.02) at day 14 of disease (FIG. 13). These lymphatics were not accompanied by any new blood vessels. Lymphangiogenic specific VEGF-D and VEGFR-3 were the earliest to increase at day 6 followed by increase in VEGF-C, VEGF-A and VEGFR-2. Increased recruitment of CD11b.sup.+/LYVE-1.sup.+ monocytic cells to the cornea was also seen with disease.
[0211] These results demonstrate that low-grade inflammation associated with dry eye is an inducer of lymphangiogenesis without accompanied hemangiogenesis.
[0212] Clinical Relevance: Demonstration of selective lymphatic growth into dry eye corneas
[0213] provides an important mechanistic link to adaptive (T cell-meditated) immunity by delineating how corneal antigen trafficking can occur to the lymphoid tissues.
[0214] Dry eye disease (DED) once thought to be solely due to deficiency of tears, is increasingly being recognized as an immune-mediated disorder) DED affects many millions of people with a wide spectrum of seminal features ranging from mild ocular discomfort to sight-threatening corneal complications such as persistent epithelial defects and sterile stromal ulceration) In the United States alone, more than 3.2 million women and 1.6 million men above the age of 50 years are affected by this potentially disabling disease adversely impacting the vision-related quality of life.
[0215] Clinically significant DED is associated with ocular surface inflammation, although the precise immunopathogenesis is not known. There is strong evidence regarding T cell involvement in the pathogenesis of DED in both animal models and humans. Recently, we illustrated T cell activation in the regional lymph nodes of dry eye mice, coincident with acquisition of specific chemokine markers which help in the homing of T cells to the inflamed ocular surface. Further we demonstrated induction of autoimmunity in the draining lymph nodes of dry eye mice due to impaired Treg function and generation of pathogenic Th17 cells. These Th17 cells were found to be resistant to Treg mediated suppression, leading to unrestrained generation ofpathogenic T cells and sustained ocular surface inflammation. Accordingly, much of the work to date has focused on understanding immunological phenomena occurring in the lymphoid compartment and the effector responses thereby generated, leaving unanswered the question as to how naive T cells in the draining lymph nodes get primed to the ocular surface antigen(s) that drive immunity in DED.
[0216] The draining lymph nodes are critical sites for induction of immunity and their role in generation of alloimmunity has been well established in corneal transplantation. The enhanced survival rate of corneal transplants in mice with excised cervical lymph nodes implicates the importance of functional flow of antigen presenting cells (APCs) from the ocular surface to the to the draining lymphoid tissue as a necessary component of alloimmunity and graft rejection. However, little is known about the pathway that allows trafficking of corneal APCs to the draining lymph nodes where they prime naive T cells to corneal antigens and generate autoimmune responses in dry eye.
[0217] Emphasis is now being given to the importance of pathological angiogenesis (hem- and lymphangiogenesis) in various corneal diseases such as different forms of keratitis, chemical burns, graft vs host disease etc., but to date there is no data regarding corneal angiogenesis in DED. A plausible reason could be that most of the above mentioned conditions except DED are accompanied by in-growth of clinically visible blood vessels into the cornea. Traditionally it has been thought that lymphatics and blood vessels which serve as afferent and efferent arms of the immune response respectively are always coexistent in pathological states. The present work provides the first evidence for selective lymphangiogenesis occurring in DED cornea using a murine model. Herein, we attempt to determine the growth of lymphatic vessels into the cornea with the progression ofDED, discuss the pathophysiologic implications of corneal lymphangiogenesis in dry eye and the potential of antilymphangiogenic therapy for ameliorating DED.
[0218] Discussion
[0219] Lymphangiogenesis in the postnatal period is primarily a response to inflammation and is seen in various pathological states as diverse as tumor metastasis, wound healing and transplantation. Lymphatics play an important role in generating immuno-inflammatory responses by directing the antigen bearing immunocytes (e.g. dendritic cells) from the periphery to the draining lymph nodes where T cells are primed and expanded. The normal human cornea is avascular, thus suppressing the afferent lymphatic and efferent vascular arms of the immune cycle. Inflammation however negates this "immune" and "angiogenic" privileged state of the cornea and gives it the potential to mount an immune response.
[0220] Angiogenesis in the cornea is now extensively being studied in various pathological models such as transplantation. Whereas corneal blood vessels have long been thought to be an important risk factor for immune rejection in corneal transplantation, it is only recently after unveiling of new lymphatic specific markers, that the significance of lymphangiogenesis in corneal alloimmunity has been characterized. Despite recognizing the role of inflammatory angiogenesis in the eye, little has hitherto been studied regarding angiogenic mechanisms in DED. Desiccating stress in DED initiates an immune-based inflammatory response that is sustained by the ongoing interplay between the ocular surface and various pathogenic immune cells, primarily the CD4.sup.+ T cells in the conjunctiva and CDI1b/monocytic cells in the cornea. Desiccating stress induces secretion of inflammatory cytokines, especially interleukin (IL)-1, tumor necrosis factor-a, and IL-6 by ocular surface tissues, which facilitate the activation and migration of resident APCs toward the regional draining LN. Our data on frequencies of mature APC in the LN also suggest increased trafficking of mature APC in
[0221] the LN of DED mice (FIG. 7). In the LN, these APCs stimulate naive T cells, leading to the
[0222] expansion ofIL-17 secreting Th17 cells and interferon (IFN)-y-secreting Th1 cells. Once these effectors are generated in the LN, they migrate to the ocular surface and secrete effector cytokines. Recent work has provided evidence for the induction of T cell mediated autoimmune responses in the regional lymph nodes of DED mice. But what has remained unanswered is how corneal APCs can traffic to the draining lymphoid compartment in order to initiate the immune cycle in DED.
[0223] Interestingly, to date there has been no published data on this important facet of immunity in DED. The data presented herein clearly demonstrates the development of lymphatic vessels in the setting of the dry eye state. These lymphatic vessels increase both in caliber and area while advancing toward the corneal center with progression of dry eye. Remarkably, these lymphatic vessels are not accompanied by growth of blood vessels. Various spatio-temporal studies examining relation between new blood and lymphatic vessels have led to the belief that a preexisting blood vascular bed is necessary to guide lymphangiogenesis. The current study refutes the general perception of wound healing models in skin where growth of lymphatic vessels follows that of blood vessels by several days. This is also in contrast to other robust models of corneal inflammation where there is either parallel outgrowth of blood and lymphatic vessels or the blood vessels are precedent over the lymphatics. This provides the first evidence of selective `natural` (non pharmacologically induced) lymphangiogeneis in a disease model that is dissociated from hemangiogenesis.
[0224] Lymphangiogenesis is mediated primarily by the interaction of growth factors VEGF-C and VEGF-D on VEGFR-2 and VEGFR-3. VEGF-A also contributes, albeit indirectly, to lymphangiogenesis by recruiting VEGF-C and VEGF-D secreting macrophages. In the present study, dry eye induction led to the up-regulation of all the VEGF growth factors and their receptors. Though the rise in levels of VEGF-A, VEGF-C and VEGFR-2 occurred at later time points (day 14), it is noteworthy, that VEGF-D and VEGFR-3 (which are both largely specific to lymphangiogenesis) increased as early as day 6 of disease. The functional relevance of the early rise of VEGF-D is highlighted in a recent study where VEGF-D, via its action on VEGFR-3, was shown to be a critical modifier of VEGF-C driven early sprouting and migration of lymphatic endothelial cells. Macrophages also seem to play a crucial role in lymphangiogenesis. Under normal physiological conditions, all ocular tissues except the central cornea are rich in bone marrow derived LYVE-1.sup.+ macrophages which may serve as precursor cells for de novo formation of lymphatics. In the present study, we noticed significantly increased number of CD11b.sup.+/LYVE-1.sup.+ cells in the peripheral corneas after exposure to desiccating stress, suggesting that either these cells infiltrate into or multiply from pre-exisiting CD1 1137 LYVE-1+ cells in the cornea, and contribute to lymphangiogenesis. Alternatively, there is a possibility of upregulation of LYVE-1 in the previous CD11b.sup.+/LYVE-1.sup.- cells.
[0225] In summary, presented herein is novel evidence for the selective growth of lymphatic (but not blood) vessels in dry eye disease providing new insights into the pathophysiology of the disease. The findings suggest that these newly formed corneal lymphatics may serve as potential conduits for migration of corneal APCs to lymphoid tissues where they generate autoreactive Th17 and Th1 cells in DED. This study not only provides a link between ocular surface inflammation and the generation of T cell mediated immunity in the lymphoid compartment, but also offers an example of how lymphangiogenesis and hemangiogenesis can be `naturally` dissociated in a pathological state. The severing of the `eye-lymphatic axis` in other immune-mediated conditions, such as transplant rejection, has been shown to hold promise as a strategy of suppressing alloimmunity without inhibiting needed innate host defense mechanisms. Similarly, a strategy targeting prolymphangiogenic factors such as VEGF-C or VEGF-D may prove effective in ameliorating dry eye disease.
Example 7
Blockade of Prolymphangiogenic VEGF-C Suppresses Dry Eye Disease
[0226] Effect of in vivo blockade of pro-lymphangiogenic VEGF-C on Dry Eye Disease Rationale: Dry eye disease (DED) is an immune-mediated disorder whose precise pathogenesis remains largely unknown. While it has been clearly established that in DED generation of pathogenic CD4.sup.+ T cells (Th1/Th17) primarily occur in the draining lymph nodes, the mechanisms of trafficking of corneal antigen presenting cells (APC) to lymphoid tissues where they activate and expand pathogenic CD4.sup.+ T cell subsets, were still not well understood prior to the invention described herein. The present invention provides evidence for the selective growth of lymphatic (but not blood) vessels in DED cornea. Data shows a significant increase in both caliber and extent of lymphatics in DED corneas which was also confirmed using real-time PCR by showing a highly significant over-expression of lymphangiogenic receptor VEGFR-3 (in contrast to a non-statistically significant increase in hemangiogenic receptor VEGFR-2 expression). This study not only provides a link between ocular surface inflammation and the generation of T-cell mediated immunity in the lymphoid compartment, but also offers an example of how lymphangiogenesis and hemangiogenesis can be `naturally` dissociated in a pathological state. Data suggests that these corneal lymphatics may serve as conduits for migration of corneal APCs to lymphoid tissues where they activate autoreactive T cells in DED.
[0227] Immunopathogenesis of DED: The pathogenesis is not fully understood. Ocular surface inflammation sustained by ongoing activation and infiltration of pathogenic immune cells. Strong evidence of T cell involvement. Recent work draining lymphoid tissue primary site for activation and generation of auto reactive effector T cells in DED (Chauhan et al; Role ofcTh17 cells in the immunopathogenesis of dry eye disease. Mucosal Immunol. 2009; 2(4):375-376.).
[0228] Expression levels of VEGF's and VEGFR's in DE corneas using RT PCR has demonstrated an increased transcript expression of VEGF-C, VEGF-D, and VEGFR-3. Thus, targeting pro-lymphangiogenic VEGF-C/D has therapeutic implications in DED.
[0229] Corneal lymphatics play an important role in mediating the corneal inflammation in dry eyes. Experiments: To validate this, inhibition of corneal neolymphangiogenesis was performed in a well characterized mouse model of DED described above. To see if inhibition of corneal neolymphangiogenesis could decrease ocular surface inflammation, anti-VEGF-C antibodies were administered i.p. daily from day -1 to day 10 to DED mice and assessed clinically using corneal fluorescein staining.
[0230] Methods (as described previously): Induction of Dry Eye Disease. Experimental Dry Eye Murine Model. Assessment of Corneal Surface: Corneal Fluorescein Staining. Immunohistochemistry: Monocyte/macrophage marker--CD11b; Pan-endothelial marker--CD31; Lymphatic endothelial marker--LYVE-1; Blood vessels: CD31hi/LYVE-1; Lymph vessels: CD31lo/LYVE-1hi. Morphometry of Lymphangiogenesis: Automated image analysis program written using Mat lab. Lymphatic Area (LA)--total surface area of the lymphatic vessels when projected into the plane of the image. Lymphatic Caliber (LC)--measure of the diameters of the lymphatic vessels.
[0231] Anti-VEGF-C antibody and treatment regimen. Experimental design: Three groups: Normal, DE group treated with IP normal Saline (Untreated) and DE group treated with anti-VEGF-C antibody (VGX-100; a gift from Vegenics, Australia). Daily IP application of anti-VEGF-C antibody /Normal saline from day -1 to day 13. Dose: 400 pg (20mg/kg) in 100 pl of Normal Saline.
[0232] The results are presented in FIG. 14. Results: The data clearly shows a significant decrease in disease severity in anti-VEGF-C-treated group compared to the untreated group. In conclusion, suppression of lymphatic growth with VEGF-C blockade led to significant improvement in DED reflected by decrease in: corneal epitheliopathy; corneal infiltration of CD11b.sup.+ cells; expression of pro-lymphangiogenic growth factors and receptors (VEGF-C, -D, R3) in DE corneas; and mRNA expression levels of pro-inflammatory cytokines in the conjunctiva.
[0233] Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. While specific embodiments of the subject invention have been discussed, the above specification is illustrative and not restrictive. Many variations of the invention will become apparent to those skilled in the art upon review of this specification. The full scope of the invention should be determined by reference to the claims, along with their full scope of equivalents, and the specification, along with such variations. Such equivalents are intended to be encompassed by the following claims.
Sequence CWU
1
1
5319PRTArtificial SequenceSynthetic peptide 1Ser Gly Tyr Trp Trp Asp Thr
Trp Phe 1 5 29PRTArtificial
SequenceSynthetic peptide 2Ser Cys Tyr Trp Arg Asp Thr Trp Phe 1
5 39PRTArtificial SequenceSynthetic peptide 3Lys
Val Gly Trp Ser Ser Pro Asp Trp 1 5
49PRTArtificial SequenceSynthetic peptide 4Phe Val Gly Trp Thr Lys Val
Leu Gly 1 5 59PRTArtificial
SequenceSynthetic peptide 5Tyr Ser Ser Ser Met Arg Trp Arg His 1
5 69PRTArtificial SequenceSynthetic peptide 6Arg
Trp Arg Gly Asn Ala Tyr Pro Gly 1 5
79PRTArtificial SequenceSynthetic peptide 7Ser Ala Val Phe Arg Gly Arg
Trp Leu 1 5 89PRTArtificial
SequenceSynthetic peptide 8Trp Phe Ser Ala Ser Leu Arg Phe Arg 1
5 98PRTArtificial SequenceSynthetic peptide 9Trp
Gln Leu Gly Arg Asn Trp Ile 1 5
108PRTArtificial SequenceSynthetic peptide 10Val Glu Val Gln Ile Thr Gln
Glu 1 5 118PRTArtificial SequenceSynthetic
peptide 11Ala Gly Lys Ala Ser Ser Leu Trp 1 5
128PRTArtificial SequenceSynthetic peptide 12Arg Ala Leu Asp Ser Ala Leu
Ala 1 5 137PRTArtificial SequenceSynthetic
peptide 13Tyr Gly Phe Glu Ala Ala Trp 1 5
147PRTArtificial SequenceSynthetic peptide 14Tyr Gly Phe Leu Trp Gly Met
1 5 157PRTArtificial SequenceSynthetic peptide
15Ser Arg Trp Arg Ile Leu Gly 1 5
167PRTArtificial SequenceSynthetic peptide 16His Lys Trp Gln Lys Arg Gln
1 5 177PRTArtificial SequenceSynthetic peptide
17Met Asp Pro Trp Gly Gly Trp 1 5
187PRTArtificial SequenceSynthetic peptide 18Arg Lys Val Trp Asp Ile Arg
1 5 196PRTArtificial SequenceSynthetic peptide
19Val Trp Asp His Gly Val 1 5 2010PRTArtificial
SequenceSynthetic peptide 20Cys Trp Gln Leu Gly Arg Asn Trp Ile Cys 1
5 10 2110PRTArtificial SequenceSynthetic
peptide 21Cys Val Glu Val Gln Ile Thr Gln Glu Cys 1 5
10 2210PRTArtificial SequenceSynthetic peptide 22Cys Ala Gly
Lys Ala Ser Ser Leu Trp Cys 1 5 10
2310PRTArtificial SequenceSynthetic peptide 23Cys Arg Ala Leu Asp Ser Ala
Leu Ala Cys 1 5 10 249PRTArtificial
SequenceSynthetic peptide 24Cys Tyr Gly Phe Glu Ala Ala Trp Cys 1
5 259PRTArtificial SequenceSynthetic peptide
25Cys Tyr Gly Phe Leu Trp Gly Met Cys 1 5
269PRTArtificial SequenceSynthetic peptide 26Cys Ser Arg Trp Arg Ile Leu
Gly Cys 1 5 279PRTArtificial
SequenceSynthetic peptide 27Cys His Lys Trp Gln Lys Arg Gln Cys 1
5 289PRTArtificial SequenceSynthetic peptide
28Cys Met Asp Pro Trp Gly Gly Trp Cys 1 5
299PRTArtificial SequenceSynthetic peptide 29Cys Arg Lys Val Trp Asp Ile
Arg Cys 1 5 308PRTArtificial
SequenceSynthetic peptide 30Cys Val Trp Asp His Gly Val Cys 1
5 3113PRTArtificial SequenceSynthetic peptide 31Cys Gly
Gln Met Cys Thr Val Trp Cys Ser Ser Gly Cys 1 5
10 327PRTArtificial SequenceSynthetic peptide 32Gly
Tyr Trp Xaa Xaa Xaa Trp 1 5 338PRTArtificial
SequenceSynthetic peptide 33Gly Tyr Trp Xaa Xaa Xaa Trp Xaa 1
5 34448PRTHomo sapiens 34Glu Val Arg Leu Leu Glu Ser Gly
Gly Gly Leu Val Gln Pro Gly Gly 1 5 10
15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe
Arg Pro Arg 20 25 30
Ala Met Ala Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45 Ser Ser Ile Ser
Ala Gln Gly Ala Ser Ala Tyr Tyr Ala Asp Ser Val 50
55 60 Lys Gly Arg Phe Thr Ile Ser Arg
Asp Asn Ser Lys Asn Thr Leu Tyr 65 70
75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala
Val Tyr Tyr Cys 85 90
95 Ala Arg Asp Leu Ser Val Ser Gly Phe Gly Pro Trp Gly Arg Gly Thr
100 105 110 Met Val Thr
Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro 115
120 125 Leu Ala Pro Ser Ser Lys Ser Thr
Ser Gly Gly Thr Ala Ala Leu Gly 130 135
140 Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val
Ser Trp Asn 145 150 155
160 Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln
165 170 175 Ser Ser Gly Leu
Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser 180
185 190 Ser Leu Gly Thr Gln Thr Tyr Ile Cys
Asn Val Asn His Lys Pro Ser 195 200
205 Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp
Lys Thr 210 215 220
His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 225
230 235 240 Val Phe Leu Phe Pro
Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 245
250 255 Thr Pro Glu Val Thr Cys Val Val Val Asp
Val Ser His Glu Asp Pro 260 265
270 Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn
Ala 275 280 285 Lys
Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val 290
295 300 Ser Val Leu Thr Val Leu
His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 305 310
315 320 Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
Pro Ile Glu Lys Thr 325 330
335 Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu
340 345 350 Pro Pro
Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys 355
360 365 Leu Val Lys Gly Phe Tyr Pro
Ser Asp Ile Ala Val Glu Trp Glu Ser 370 375
380 Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro
Pro Val Leu Asp 385 390 395
400 Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser
405 410 415 Arg Trp Gln
Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 420
425 430 Leu His Asn His Tyr Thr Gln Lys
Ser Leu Ser Leu Ser Pro Gly Lys 435 440
445 35217PRTHomo sapiens 35Ser Tyr Glu Leu Thr Gln Pro
Pro Ser Ser Ser Gly Thr Pro Gly Gln 1 5
10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser
Asn Ile Gly Arg His 20 25
30 Thr Val Ser Trp Tyr Gln Gln Val Pro Gly Thr Ala Pro Lys Leu
Leu 35 40 45 Ile
Tyr Ser Asp Asp His Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50
55 60 Ala Ser Lys Ser Gly Thr
Ser Ala Ser Leu Thr Ile Thr Gly Leu Gln 65 70
75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala
Trp Asp Asp Ser Leu 85 90
95 Asn Gly Pro Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly
100 105 110 Gln Pro
Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu 115
120 125 Glu Leu Gln Ala Asn Lys Ala
Thr Leu Val Cys Leu Ile Ser Asp Phe 130 135
140 Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp
Ser Ser Pro Val 145 150 155
160 Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys
165 170 175 Tyr Ala Ala
Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser 180
185 190 His Arg Ser Tyr Ser Cys Gln Val
Thr His Glu Gly Ser Thr Val Glu 195 200
205 Lys Thr Val Ala Pro Thr Glu Cys Ser 210
215 362292DNAHomo sapiensCDS(1)..(2292) 36atg gag agc aag
gtg ctg ctg gcc gtc gcc ctg tgg ctc tgc gtg gag 48Met Glu Ser Lys
Val Leu Leu Ala Val Ala Leu Trp Leu Cys Val Glu 1 5
10 15 acc cgg gcc gcc tct
gtg ggt ttg cct agt gtt tct ctt gat ctg ccc 96Thr Arg Ala Ala Ser
Val Gly Leu Pro Ser Val Ser Leu Asp Leu Pro 20
25 30 agg ctc agc ata caa aaa
gac ata ctt aca att aag gct aat aca act 144Arg Leu Ser Ile Gln Lys
Asp Ile Leu Thr Ile Lys Ala Asn Thr Thr 35
40 45 ctt caa att act tgc agg gga
cag agg gac ttg gac tgg ctt tgg ccc 192Leu Gln Ile Thr Cys Arg Gly
Gln Arg Asp Leu Asp Trp Leu Trp Pro 50 55
60 aat aat cag agt ggc agt gag caa
agg gtg gag gtg act gag tgc agc 240Asn Asn Gln Ser Gly Ser Glu Gln
Arg Val Glu Val Thr Glu Cys Ser 65 70
75 80 gat ggc ctc ttc tgt aag aca ctc aca
att cca aaa gtg atc gga aat 288Asp Gly Leu Phe Cys Lys Thr Leu Thr
Ile Pro Lys Val Ile Gly Asn 85
90 95 gac act gga gcc tac aag tgc ttc tac
cgg gaa act gac ttg gcc tcg 336Asp Thr Gly Ala Tyr Lys Cys Phe Tyr
Arg Glu Thr Asp Leu Ala Ser 100 105
110 gtc att tat gtc tat gtt caa gat tac aga
tct cca ttt att gct tct 384Val Ile Tyr Val Tyr Val Gln Asp Tyr Arg
Ser Pro Phe Ile Ala Ser 115 120
125 gtt agt gac caa cat gga gtc gtg tac att act
gag aac aaa aac aaa 432Val Ser Asp Gln His Gly Val Val Tyr Ile Thr
Glu Asn Lys Asn Lys 130 135
140 act gtg gtg att cca tgt ctc ggg tcc att tca
aat ctc aac gtg tca 480Thr Val Val Ile Pro Cys Leu Gly Ser Ile Ser
Asn Leu Asn Val Ser 145 150 155
160 ctt tgt gca aga tac cca gaa aag aga ttt gtt cct
gat ggt aac aga 528Leu Cys Ala Arg Tyr Pro Glu Lys Arg Phe Val Pro
Asp Gly Asn Arg 165 170
175 att tcc tgg gac agc aag aag ggc ttt act att ccc agc
tac atg atc 576Ile Ser Trp Asp Ser Lys Lys Gly Phe Thr Ile Pro Ser
Tyr Met Ile 180 185
190 agc tat gct ggc atg gtc ttc tgt gaa gca aaa att aat
gat gaa agt 624Ser Tyr Ala Gly Met Val Phe Cys Glu Ala Lys Ile Asn
Asp Glu Ser 195 200 205
tac cag tct att atg tac ata gtt gtc gtt gta ggg tat agg
att tat 672Tyr Gln Ser Ile Met Tyr Ile Val Val Val Val Gly Tyr Arg
Ile Tyr 210 215 220
gat gtg gtt ctg agt ccg tct cat gga att gaa cta tct gtt gga
gaa 720Asp Val Val Leu Ser Pro Ser His Gly Ile Glu Leu Ser Val Gly
Glu 225 230 235
240 aag ctt gtc tta aat tgt aca gca aga act gaa cta aat gtg ggg
att 768Lys Leu Val Leu Asn Cys Thr Ala Arg Thr Glu Leu Asn Val Gly
Ile 245 250 255
gac ttc aac tgg gaa tac cct tct tcg aag cat cag cat aag aaa ctt
816Asp Phe Asn Trp Glu Tyr Pro Ser Ser Lys His Gln His Lys Lys Leu
260 265 270
gta aac cga gac cta aaa acc cag tct ggg agt gag atg aag aaa ttt
864Val Asn Arg Asp Leu Lys Thr Gln Ser Gly Ser Glu Met Lys Lys Phe
275 280 285
ttg agc acc tta act ata gat ggt gta acc cgg agt gac caa gga ttg
912Leu Ser Thr Leu Thr Ile Asp Gly Val Thr Arg Ser Asp Gln Gly Leu
290 295 300
tac acc tgt gca gca tcc agt ggg ctg atg acc aag aag aac agc aca
960Tyr Thr Cys Ala Ala Ser Ser Gly Leu Met Thr Lys Lys Asn Ser Thr
305 310 315 320
ttt gtc agg gtc cat gaa aaa cct ttt gtt gct ttt gga agt ggc atg
1008Phe Val Arg Val His Glu Lys Pro Phe Val Ala Phe Gly Ser Gly Met
325 330 335
gaa tct ctg gtg gaa gcc acg gtg ggg gag cgt gtc aga atc cct gcg
1056Glu Ser Leu Val Glu Ala Thr Val Gly Glu Arg Val Arg Ile Pro Ala
340 345 350
aag tac ctt ggt tac cca ccc cca gaa ata aaa tgg tat aaa aat gga
1104Lys Tyr Leu Gly Tyr Pro Pro Pro Glu Ile Lys Trp Tyr Lys Asn Gly
355 360 365
ata ccc ctt gag tcc aat cac aca att aaa gcg ggg cat gta ctg acg
1152Ile Pro Leu Glu Ser Asn His Thr Ile Lys Ala Gly His Val Leu Thr
370 375 380
att atg gaa gtg agt gaa aga gac aca gga aat tac act gtc atc ctt
1200Ile Met Glu Val Ser Glu Arg Asp Thr Gly Asn Tyr Thr Val Ile Leu
385 390 395 400
acc aat ccc att tca aag gag aag cag agc cat gtg gtc tct ctg gtt
1248Thr Asn Pro Ile Ser Lys Glu Lys Gln Ser His Val Val Ser Leu Val
405 410 415
gtg tat gtc cca ccc cag att ggt gag aaa tct cta atc tct cct gtg
1296Val Tyr Val Pro Pro Gln Ile Gly Glu Lys Ser Leu Ile Ser Pro Val
420 425 430
gat tcc tac cag tac ggc acc act caa acg ctg aca tgt acg gtc tat
1344Asp Ser Tyr Gln Tyr Gly Thr Thr Gln Thr Leu Thr Cys Thr Val Tyr
435 440 445
gcc att cct ccc ccg cat cac atc cac tgg tat tgg cag ttg gag gaa
1392Ala Ile Pro Pro Pro His His Ile His Trp Tyr Trp Gln Leu Glu Glu
450 455 460
gag tgc gcc aac gag ccc agc caa gct gtc tca gtg aca aac cca tac
1440Glu Cys Ala Asn Glu Pro Ser Gln Ala Val Ser Val Thr Asn Pro Tyr
465 470 475 480
cct tgt gaa gaa tgg aga agt gtg gag gac ttc cag gga gga aat aaa
1488Pro Cys Glu Glu Trp Arg Ser Val Glu Asp Phe Gln Gly Gly Asn Lys
485 490 495
att gaa gtt aat aaa aat caa ttt gct cta att gaa gga aaa aac aaa
1536Ile Glu Val Asn Lys Asn Gln Phe Ala Leu Ile Glu Gly Lys Asn Lys
500 505 510
act gta agt acc ctt gtt atc caa gcg gca aat gtg tca gct ttg tac
1584Thr Val Ser Thr Leu Val Ile Gln Ala Ala Asn Val Ser Ala Leu Tyr
515 520 525
aaa tgt gaa gcg gtc aac aaa gtc ggg aga gga gag agg gtg atc tcc
1632Lys Cys Glu Ala Val Asn Lys Val Gly Arg Gly Glu Arg Val Ile Ser
530 535 540
ttc cac gtg acc agg ggt cct gaa att act ttg caa cct gac atg cag
1680Phe His Val Thr Arg Gly Pro Glu Ile Thr Leu Gln Pro Asp Met Gln
545 550 555 560
ccc act gag cag gag agc gtg tct ttg tgg tgc act gca gac aga tct
1728Pro Thr Glu Gln Glu Ser Val Ser Leu Trp Cys Thr Ala Asp Arg Ser
565 570 575
acg ttt gag aac ctc aca tgg tac aag ctt ggc cca cag cct ctg cca
1776Thr Phe Glu Asn Leu Thr Trp Tyr Lys Leu Gly Pro Gln Pro Leu Pro
580 585 590
atc cat gtg gga gag ttg ccc aca cct gtt tgc aag aac ttg gat act
1824Ile His Val Gly Glu Leu Pro Thr Pro Val Cys Lys Asn Leu Asp Thr
595 600 605
ctt tgg aaa ttg aat gcc acc atg ttc tct aat agc aca aat gac att
1872Leu Trp Lys Leu Asn Ala Thr Met Phe Ser Asn Ser Thr Asn Asp Ile
610 615 620
ttg atc atg gag ctt aag aat gca tcc ttg cag gac caa gga gac tat
1920Leu Ile Met Glu Leu Lys Asn Ala Ser Leu Gln Asp Gln Gly Asp Tyr
625 630 635 640
gtc tgc ctt gct caa gac agg aag acc aag aaa aga cat tgc gtg gtc
1968Val Cys Leu Ala Gln Asp Arg Lys Thr Lys Lys Arg His Cys Val Val
645 650 655
agg cag ctc aca gtc cta gag cgt gtg gca ccc acg atc aca gga aac
2016Arg Gln Leu Thr Val Leu Glu Arg Val Ala Pro Thr Ile Thr Gly Asn
660 665 670
ctg gag aat cag acg aca agt att ggg gaa agc atc gaa gtc tca tgc
2064Leu Glu Asn Gln Thr Thr Ser Ile Gly Glu Ser Ile Glu Val Ser Cys
675 680 685
acg gca tct ggg aat ccc cct cca cag atc atg tgg ttt aaa gat aat
2112Thr Ala Ser Gly Asn Pro Pro Pro Gln Ile Met Trp Phe Lys Asp Asn
690 695 700
gag acc ctt gta gaa gac tca ggc att gta ttg aag gat ggg aac cgg
2160Glu Thr Leu Val Glu Asp Ser Gly Ile Val Leu Lys Asp Gly Asn Arg
705 710 715 720
aac ctc act atc cgc aga gtg agg aag gag gac gaa ggc ctc tac acc
2208Asn Leu Thr Ile Arg Arg Val Arg Lys Glu Asp Glu Gly Leu Tyr Thr
725 730 735
tgc cag gca tgc agt gtt ctt ggc tgt gca aaa gtg gag gca ttt ttc
2256Cys Gln Ala Cys Ser Val Leu Gly Cys Ala Lys Val Glu Ala Phe Phe
740 745 750
ata ata gaa ggt gcc cag gaa aag acg aac ttg gaa
2292Ile Ile Glu Gly Ala Gln Glu Lys Thr Asn Leu Glu
755 760
37764PRTHomo sapiens 37Met Glu Ser Lys Val Leu Leu Ala Val Ala Leu Trp
Leu Cys Val Glu 1 5 10
15 Thr Arg Ala Ala Ser Val Gly Leu Pro Ser Val Ser Leu Asp Leu Pro
20 25 30 Arg Leu Ser
Ile Gln Lys Asp Ile Leu Thr Ile Lys Ala Asn Thr Thr 35
40 45 Leu Gln Ile Thr Cys Arg Gly Gln
Arg Asp Leu Asp Trp Leu Trp Pro 50 55
60 Asn Asn Gln Ser Gly Ser Glu Gln Arg Val Glu Val Thr
Glu Cys Ser 65 70 75
80 Asp Gly Leu Phe Cys Lys Thr Leu Thr Ile Pro Lys Val Ile Gly Asn
85 90 95 Asp Thr Gly Ala
Tyr Lys Cys Phe Tyr Arg Glu Thr Asp Leu Ala Ser 100
105 110 Val Ile Tyr Val Tyr Val Gln Asp Tyr
Arg Ser Pro Phe Ile Ala Ser 115 120
125 Val Ser Asp Gln His Gly Val Val Tyr Ile Thr Glu Asn Lys
Asn Lys 130 135 140
Thr Val Val Ile Pro Cys Leu Gly Ser Ile Ser Asn Leu Asn Val Ser 145
150 155 160 Leu Cys Ala Arg Tyr
Pro Glu Lys Arg Phe Val Pro Asp Gly Asn Arg 165
170 175 Ile Ser Trp Asp Ser Lys Lys Gly Phe Thr
Ile Pro Ser Tyr Met Ile 180 185
190 Ser Tyr Ala Gly Met Val Phe Cys Glu Ala Lys Ile Asn Asp Glu
Ser 195 200 205 Tyr
Gln Ser Ile Met Tyr Ile Val Val Val Val Gly Tyr Arg Ile Tyr 210
215 220 Asp Val Val Leu Ser Pro
Ser His Gly Ile Glu Leu Ser Val Gly Glu 225 230
235 240 Lys Leu Val Leu Asn Cys Thr Ala Arg Thr Glu
Leu Asn Val Gly Ile 245 250
255 Asp Phe Asn Trp Glu Tyr Pro Ser Ser Lys His Gln His Lys Lys Leu
260 265 270 Val Asn
Arg Asp Leu Lys Thr Gln Ser Gly Ser Glu Met Lys Lys Phe 275
280 285 Leu Ser Thr Leu Thr Ile Asp
Gly Val Thr Arg Ser Asp Gln Gly Leu 290 295
300 Tyr Thr Cys Ala Ala Ser Ser Gly Leu Met Thr Lys
Lys Asn Ser Thr 305 310 315
320 Phe Val Arg Val His Glu Lys Pro Phe Val Ala Phe Gly Ser Gly Met
325 330 335 Glu Ser Leu
Val Glu Ala Thr Val Gly Glu Arg Val Arg Ile Pro Ala 340
345 350 Lys Tyr Leu Gly Tyr Pro Pro Pro
Glu Ile Lys Trp Tyr Lys Asn Gly 355 360
365 Ile Pro Leu Glu Ser Asn His Thr Ile Lys Ala Gly His
Val Leu Thr 370 375 380
Ile Met Glu Val Ser Glu Arg Asp Thr Gly Asn Tyr Thr Val Ile Leu 385
390 395 400 Thr Asn Pro Ile
Ser Lys Glu Lys Gln Ser His Val Val Ser Leu Val 405
410 415 Val Tyr Val Pro Pro Gln Ile Gly Glu
Lys Ser Leu Ile Ser Pro Val 420 425
430 Asp Ser Tyr Gln Tyr Gly Thr Thr Gln Thr Leu Thr Cys Thr
Val Tyr 435 440 445
Ala Ile Pro Pro Pro His His Ile His Trp Tyr Trp Gln Leu Glu Glu 450
455 460 Glu Cys Ala Asn Glu
Pro Ser Gln Ala Val Ser Val Thr Asn Pro Tyr 465 470
475 480 Pro Cys Glu Glu Trp Arg Ser Val Glu Asp
Phe Gln Gly Gly Asn Lys 485 490
495 Ile Glu Val Asn Lys Asn Gln Phe Ala Leu Ile Glu Gly Lys Asn
Lys 500 505 510 Thr
Val Ser Thr Leu Val Ile Gln Ala Ala Asn Val Ser Ala Leu Tyr 515
520 525 Lys Cys Glu Ala Val Asn
Lys Val Gly Arg Gly Glu Arg Val Ile Ser 530 535
540 Phe His Val Thr Arg Gly Pro Glu Ile Thr Leu
Gln Pro Asp Met Gln 545 550 555
560 Pro Thr Glu Gln Glu Ser Val Ser Leu Trp Cys Thr Ala Asp Arg Ser
565 570 575 Thr Phe
Glu Asn Leu Thr Trp Tyr Lys Leu Gly Pro Gln Pro Leu Pro 580
585 590 Ile His Val Gly Glu Leu Pro
Thr Pro Val Cys Lys Asn Leu Asp Thr 595 600
605 Leu Trp Lys Leu Asn Ala Thr Met Phe Ser Asn Ser
Thr Asn Asp Ile 610 615 620
Leu Ile Met Glu Leu Lys Asn Ala Ser Leu Gln Asp Gln Gly Asp Tyr 625
630 635 640 Val Cys Leu
Ala Gln Asp Arg Lys Thr Lys Lys Arg His Cys Val Val 645
650 655 Arg Gln Leu Thr Val Leu Glu Arg
Val Ala Pro Thr Ile Thr Gly Asn 660 665
670 Leu Glu Asn Gln Thr Thr Ser Ile Gly Glu Ser Ile Glu
Val Ser Cys 675 680 685
Thr Ala Ser Gly Asn Pro Pro Pro Gln Ile Met Trp Phe Lys Asp Asn 690
695 700 Glu Thr Leu Val
Glu Asp Ser Gly Ile Val Leu Lys Asp Gly Asn Arg 705 710
715 720 Asn Leu Thr Ile Arg Arg Val Arg Lys
Glu Asp Glu Gly Leu Tyr Thr 725 730
735 Cys Gln Ala Cys Ser Val Leu Gly Cys Ala Lys Val Glu Ala
Phe Phe 740 745 750
Ile Ile Glu Gly Ala Gln Glu Lys Thr Asn Leu Glu 755
760 384195DNAHomo sapiensCDS(20)..(3913) 38ccacgcgcag
cggccggag atg cag cgg ggc gcc gcg ctg tgc ctg cga ctg 52
Met Gln Arg Gly Ala Ala Leu Cys Leu Arg Leu
1 5 10 tgg ctc tgc ctg
gga ctc ctg gac ggc ctg gtg agt ggc tac tcc atg 100Trp Leu Cys Leu
Gly Leu Leu Asp Gly Leu Val Ser Gly Tyr Ser Met 15
20 25 acc ccc ccg acc ttg
aac atc acg gag gag tca cac gtc atc gac acc 148Thr Pro Pro Thr Leu
Asn Ile Thr Glu Glu Ser His Val Ile Asp Thr 30
35 40 ggt gac agc ctg tcc atc
tcc tgc agg gga cag cac ccc ctc gag tgg 196Gly Asp Ser Leu Ser Ile
Ser Cys Arg Gly Gln His Pro Leu Glu Trp 45
50 55 gct tgg cca gga gct cag
gag gcg cca gcc acc gga gac aag gac agc 244Ala Trp Pro Gly Ala Gln
Glu Ala Pro Ala Thr Gly Asp Lys Asp Ser 60 65
70 75 gag gac acg ggg gtg gtg cga
gac tgc gag ggc aca gac gcc agg ccc 292Glu Asp Thr Gly Val Val Arg
Asp Cys Glu Gly Thr Asp Ala Arg Pro 80
85 90 tac tgc aag gtg ttg ctg ctg cac
gag gta cat gcc aac gac aca ggc 340Tyr Cys Lys Val Leu Leu Leu His
Glu Val His Ala Asn Asp Thr Gly 95
100 105 agc tac gtc tgc tac tac aag tac
atc aag gca cgc atc gag ggc acc 388Ser Tyr Val Cys Tyr Tyr Lys Tyr
Ile Lys Ala Arg Ile Glu Gly Thr 110 115
120 acg gcc gcc agc tcc tac gtg ttc gtg
aga gac ttt gag cag cca ttc 436Thr Ala Ala Ser Ser Tyr Val Phe Val
Arg Asp Phe Glu Gln Pro Phe 125 130
135 atc aac aag cct gac acg ctc ttg gtc aac
agg aag gac gcc atg tgg 484Ile Asn Lys Pro Asp Thr Leu Leu Val Asn
Arg Lys Asp Ala Met Trp 140 145
150 155 gtg ccc tgt ctg gtg tcc atc ccc ggc ctc
aat gtc acg ctg cgc tcg 532Val Pro Cys Leu Val Ser Ile Pro Gly Leu
Asn Val Thr Leu Arg Ser 160 165
170 caa agc tcg gtg ctg tgg cca gac ggg cag gag
gtg gtg tgg gat gac 580Gln Ser Ser Val Leu Trp Pro Asp Gly Gln Glu
Val Val Trp Asp Asp 175 180
185 cgg cgg ggc atg ctc gtg tcc acg cca ctg ctg cac
gat gcc ctg tac 628Arg Arg Gly Met Leu Val Ser Thr Pro Leu Leu His
Asp Ala Leu Tyr 190 195
200 ctg cag tgc gag acc acc tgg gga gac cag gac ttc
ctt tcc aac ccc 676Leu Gln Cys Glu Thr Thr Trp Gly Asp Gln Asp Phe
Leu Ser Asn Pro 205 210 215
ttc ctg gtg cac atc aca ggc aac gag ctc tat gac atc
cag ctg ttg 724Phe Leu Val His Ile Thr Gly Asn Glu Leu Tyr Asp Ile
Gln Leu Leu 220 225 230
235 ccc agg aag tcg ctg gag ctg ctg gta ggg gag aag ctg gtc
ctg aac 772Pro Arg Lys Ser Leu Glu Leu Leu Val Gly Glu Lys Leu Val
Leu Asn 240 245
250 tgc acc gtg tgg gct gag ttt aac tca ggt gtc acc ttt gac
tgg gac 820Cys Thr Val Trp Ala Glu Phe Asn Ser Gly Val Thr Phe Asp
Trp Asp 255 260 265
tac cca ggg aag cag gca gag cgg ggt aag tgg gtg ccc gag cga
cgc 868Tyr Pro Gly Lys Gln Ala Glu Arg Gly Lys Trp Val Pro Glu Arg
Arg 270 275 280
tcc cag cag acc cac aca gaa ctc tcc agc atc ctg acc atc cac aac
916Ser Gln Gln Thr His Thr Glu Leu Ser Ser Ile Leu Thr Ile His Asn
285 290 295
gtc agc cag cac gac ctg ggc tcg tat gtg tgc aag gcc aac aac ggc
964Val Ser Gln His Asp Leu Gly Ser Tyr Val Cys Lys Ala Asn Asn Gly
300 305 310 315
atc cag cga ttt cgg gag agc acc gag gtc att gtg cat gaa aat ccc
1012Ile Gln Arg Phe Arg Glu Ser Thr Glu Val Ile Val His Glu Asn Pro
320 325 330
ttc atc agc gtc gag tgg ctc aaa gga ccc atc ctg gag gcc acg gca
1060Phe Ile Ser Val Glu Trp Leu Lys Gly Pro Ile Leu Glu Ala Thr Ala
335 340 345
gga gac gag ctg gtg aag ctg ccc gtg aag ctg gca gcg tac ccc ccg
1108Gly Asp Glu Leu Val Lys Leu Pro Val Lys Leu Ala Ala Tyr Pro Pro
350 355 360
ccc gag ttc cag tgg tac aag gat gga aag gca ctg tcc ggg cgc cac
1156Pro Glu Phe Gln Trp Tyr Lys Asp Gly Lys Ala Leu Ser Gly Arg His
365 370 375
agt cca cat gcc ctg gtg ctc aag gag gtg aca gag gcc agc aca ggc
1204Ser Pro His Ala Leu Val Leu Lys Glu Val Thr Glu Ala Ser Thr Gly
380 385 390 395
acc tac acc ctc gcc ctg tgg aac tcc gct gct ggc ctg agg cgc aac
1252Thr Tyr Thr Leu Ala Leu Trp Asn Ser Ala Ala Gly Leu Arg Arg Asn
400 405 410
atc agc ctg gag ctg gtg gtg aat gtg ccc ccc cag ata cat gag aag
1300Ile Ser Leu Glu Leu Val Val Asn Val Pro Pro Gln Ile His Glu Lys
415 420 425
gag gcc tcc tcc ccc agc atc tac tcg cgt cac agc cgc cag gcc ctc
1348Glu Ala Ser Ser Pro Ser Ile Tyr Ser Arg His Ser Arg Gln Ala Leu
430 435 440
acc tgc acg gcc tac ggg gtg ccc ctg cct ctc agc atc cag tgg cac
1396Thr Cys Thr Ala Tyr Gly Val Pro Leu Pro Leu Ser Ile Gln Trp His
445 450 455
tgg cgg ccc tgg aca ccc tgc aag atg ttt gcc cag cgt agt ctc cgg
1444Trp Arg Pro Trp Thr Pro Cys Lys Met Phe Ala Gln Arg Ser Leu Arg
460 465 470 475
cgg cgg cag cag caa gac ctc atg cca cag tgc cgt gac tgg agg gcg
1492Arg Arg Gln Gln Gln Asp Leu Met Pro Gln Cys Arg Asp Trp Arg Ala
480 485 490
gtg acc acg cag gat gcc gtg aac ccc atc gag agc ctg gac acc tgg
1540Val Thr Thr Gln Asp Ala Val Asn Pro Ile Glu Ser Leu Asp Thr Trp
495 500 505
acc gag ttt gtg gag gga aag aat aag act gtg agc aag ctg gtg atc
1588Thr Glu Phe Val Glu Gly Lys Asn Lys Thr Val Ser Lys Leu Val Ile
510 515 520
cag aat gcc aac gtg tct gcc atg tac aag tgt gtg gtc tcc aac aag
1636Gln Asn Ala Asn Val Ser Ala Met Tyr Lys Cys Val Val Ser Asn Lys
525 530 535
gtg ggc cag gat gag cgg ctc atc tac ttc tat gtg acc acc atc ccc
1684Val Gly Gln Asp Glu Arg Leu Ile Tyr Phe Tyr Val Thr Thr Ile Pro
540 545 550 555
gac ggc ttc acc atc gaa tcc aag cca tcc gag gag cta cta gag ggc
1732Asp Gly Phe Thr Ile Glu Ser Lys Pro Ser Glu Glu Leu Leu Glu Gly
560 565 570
cag ccg gtg ctc ctg agc tgc caa gcc gac agc tac aag tac gag cat
1780Gln Pro Val Leu Leu Ser Cys Gln Ala Asp Ser Tyr Lys Tyr Glu His
575 580 585
ctg cgc tgg tac cgc ctc aac ctg tcc acg ctg cac gat gcg cac ggg
1828Leu Arg Trp Tyr Arg Leu Asn Leu Ser Thr Leu His Asp Ala His Gly
590 595 600
aac ccg ctt ctg ctc gac tgc aag aac gtg cat ctg ttc gcc acc cct
1876Asn Pro Leu Leu Leu Asp Cys Lys Asn Val His Leu Phe Ala Thr Pro
605 610 615
ctg gcc gcc agc ctg gag gag gtg gca cct ggg gcg cgc cac gcc acg
1924Leu Ala Ala Ser Leu Glu Glu Val Ala Pro Gly Ala Arg His Ala Thr
620 625 630 635
ctc agc ctg agt atc ccc cgc gtc gcg ccc gag cac gag ggc cac tat
1972Leu Ser Leu Ser Ile Pro Arg Val Ala Pro Glu His Glu Gly His Tyr
640 645 650
gtg tgc gaa gtg caa gac cgg cgc agc cat gac aag cac tgc cac aag
2020Val Cys Glu Val Gln Asp Arg Arg Ser His Asp Lys His Cys His Lys
655 660 665
aag tac ctg tcg gtg cag gcc ctg gaa gcc cct cgg ctc acg cag aac
2068Lys Tyr Leu Ser Val Gln Ala Leu Glu Ala Pro Arg Leu Thr Gln Asn
670 675 680
ttg acc gac ctc ctg gtg aac gtg agc gac tcg ctg gag atg cag tgc
2116Leu Thr Asp Leu Leu Val Asn Val Ser Asp Ser Leu Glu Met Gln Cys
685 690 695
ttg gtg gcc gga gcg cac gcg ccc agc atc gtg tgg tac aaa gac gag
2164Leu Val Ala Gly Ala His Ala Pro Ser Ile Val Trp Tyr Lys Asp Glu
700 705 710 715
agg ctg ctg gag gaa aag tct gga gtc gac ttg gcg gac tcc aac cag
2212Arg Leu Leu Glu Glu Lys Ser Gly Val Asp Leu Ala Asp Ser Asn Gln
720 725 730
aag ctg agc atc cag cgc gtg cgc gag gag gat gcg gga cgc tat ctg
2260Lys Leu Ser Ile Gln Arg Val Arg Glu Glu Asp Ala Gly Arg Tyr Leu
735 740 745
tgc agc gtg tgc aac gcc aag ggc tgc gtc aac tcc tcc gcc agc gtg
2308Cys Ser Val Cys Asn Ala Lys Gly Cys Val Asn Ser Ser Ala Ser Val
750 755 760
gcc gtg gaa ggc tcc gag gat aag ggc agc atg gag atc gtg atc ctt
2356Ala Val Glu Gly Ser Glu Asp Lys Gly Ser Met Glu Ile Val Ile Leu
765 770 775
gtc ggt acc ggc gtc atc gct gtc ttc ttc tgg gtc ctc ctc ctc ctc
2404Val Gly Thr Gly Val Ile Ala Val Phe Phe Trp Val Leu Leu Leu Leu
780 785 790 795
atc ttc tgt aac atg agg agg ccg gcc cac gca gac atc aag acg ggc
2452Ile Phe Cys Asn Met Arg Arg Pro Ala His Ala Asp Ile Lys Thr Gly
800 805 810
tac ctg tcc atc atc atg gac ccc ggg gag gtg cct ctg gag gag caa
2500Tyr Leu Ser Ile Ile Met Asp Pro Gly Glu Val Pro Leu Glu Glu Gln
815 820 825
tgc gaa tac ctg tcc tac gat gcc agc cag tgg gaa ttc ccc cga gag
2548Cys Glu Tyr Leu Ser Tyr Asp Ala Ser Gln Trp Glu Phe Pro Arg Glu
830 835 840
cgg ctg cac ctg ggg aga gtg ctc ggc tac ggc gcc ttc ggg aag gtg
2596Arg Leu His Leu Gly Arg Val Leu Gly Tyr Gly Ala Phe Gly Lys Val
845 850 855
gtg gaa gcc tcc gct ttc ggc atc cac aag ggc agc agc tgt gac acc
2644Val Glu Ala Ser Ala Phe Gly Ile His Lys Gly Ser Ser Cys Asp Thr
860 865 870 875
gtg gcc gtg aaa atg ctg aaa gag ggc gcc acg gcc agc gag cac cgc
2692Val Ala Val Lys Met Leu Lys Glu Gly Ala Thr Ala Ser Glu His Arg
880 885 890
gcg ctg atg tcg gag ctc aag atc ctc att cac atc ggc aac cac ctc
2740Ala Leu Met Ser Glu Leu Lys Ile Leu Ile His Ile Gly Asn His Leu
895 900 905
aac gtg gtc aac ctc ctc ggg gcg tgc acc aag ccg cag ggc ccc ctc
2788Asn Val Val Asn Leu Leu Gly Ala Cys Thr Lys Pro Gln Gly Pro Leu
910 915 920
atg gtg atc gtg gag ttc tgc aag tac ggc aac ctc tcc aac ttc ctg
2836Met Val Ile Val Glu Phe Cys Lys Tyr Gly Asn Leu Ser Asn Phe Leu
925 930 935
cgc gcc aag cgg gac gcc ttc agc ccc tgc gcg gag aag tct ccc gag
2884Arg Ala Lys Arg Asp Ala Phe Ser Pro Cys Ala Glu Lys Ser Pro Glu
940 945 950 955
cag cgc gga cgc ttc cgc gcc atg gtg gag ctc gcc agg ctg gat cgg
2932Gln Arg Gly Arg Phe Arg Ala Met Val Glu Leu Ala Arg Leu Asp Arg
960 965 970
agg cgg ccg ggg agc agc gac agg gtc ctc ttc gcg cgg ttc tcg aag
2980Arg Arg Pro Gly Ser Ser Asp Arg Val Leu Phe Ala Arg Phe Ser Lys
975 980 985
acc gag ggc gga gcg agg cgg gct tct cca gac caa gaa gct gag gac
3028Thr Glu Gly Gly Ala Arg Arg Ala Ser Pro Asp Gln Glu Ala Glu Asp
990 995 1000
ctg tgg ctg agc ccg ctg acc atg gaa gat ctt gtc tgc tac agc
3073Leu Trp Leu Ser Pro Leu Thr Met Glu Asp Leu Val Cys Tyr Ser
1005 1010 1015
ttc cag gtg gcc aga ggg atg gag ttc ctg gct tcc cga aag tgc
3118Phe Gln Val Ala Arg Gly Met Glu Phe Leu Ala Ser Arg Lys Cys
1020 1025 1030
atc cac aga gac ctg gct gct cgg aac att ctg ctg tcg gaa agc
3163Ile His Arg Asp Leu Ala Ala Arg Asn Ile Leu Leu Ser Glu Ser
1035 1040 1045
gac gtg gtg aag atc tgt gac ttt ggc ctt gcc cgg gac atc tac
3208Asp Val Val Lys Ile Cys Asp Phe Gly Leu Ala Arg Asp Ile Tyr
1050 1055 1060
aaa gac cct gac tac gtc cgc aag ggc agt gcc cgg ctg ccc ctg
3253Lys Asp Pro Asp Tyr Val Arg Lys Gly Ser Ala Arg Leu Pro Leu
1065 1070 1075
aag tgg atg gcc cct gaa agc atc ttc gac aag gtg tac acc acg
3298Lys Trp Met Ala Pro Glu Ser Ile Phe Asp Lys Val Tyr Thr Thr
1080 1085 1090
cag agt gac gtg tgg tcc ttt ggg gtg ctt ctc tgg gag atc ttc
3343Gln Ser Asp Val Trp Ser Phe Gly Val Leu Leu Trp Glu Ile Phe
1095 1100 1105
tct ctg ggg gcc tcc ccg tac cct ggg gtg cag atc aat gag gag
3388Ser Leu Gly Ala Ser Pro Tyr Pro Gly Val Gln Ile Asn Glu Glu
1110 1115 1120
ttc tgc cag cgg ctg aga gac ggc aca agg atg agg gcc ccg gag
3433Phe Cys Gln Arg Leu Arg Asp Gly Thr Arg Met Arg Ala Pro Glu
1125 1130 1135
ctg gcc act ccc gcc ata cgc cgc atc atg ctg aac tgc tgg tcc
3478Leu Ala Thr Pro Ala Ile Arg Arg Ile Met Leu Asn Cys Trp Ser
1140 1145 1150
gga gac ccc aag gcg aga cct gca ttc tcg gag ctg gtg gag atc
3523Gly Asp Pro Lys Ala Arg Pro Ala Phe Ser Glu Leu Val Glu Ile
1155 1160 1165
ctg ggg gac ctg ctc cag ggc agg ggc ctg caa gag gaa gag gag
3568Leu Gly Asp Leu Leu Gln Gly Arg Gly Leu Gln Glu Glu Glu Glu
1170 1175 1180
gtc tgc atg gcc ccg cgc agc tct cag agc tca gaa gag ggc agc
3613Val Cys Met Ala Pro Arg Ser Ser Gln Ser Ser Glu Glu Gly Ser
1185 1190 1195
ttc tcg cag gtg tcc acc atg gcc cta cac atc gcc cag gct gac
3658Phe Ser Gln Val Ser Thr Met Ala Leu His Ile Ala Gln Ala Asp
1200 1205 1210
gct gag gac agc ccg cca agc ctg cag cgc cac agc ctg gcc gcc
3703Ala Glu Asp Ser Pro Pro Ser Leu Gln Arg His Ser Leu Ala Ala
1215 1220 1225
agg tat tac aac tgg gtg tcc ttt ccc ggg tgc ctg gcc aga ggg
3748Arg Tyr Tyr Asn Trp Val Ser Phe Pro Gly Cys Leu Ala Arg Gly
1230 1235 1240
gct gag acc cgt ggt tcc tcc agg atg aag aca ttt gag gaa ttc
3793Ala Glu Thr Arg Gly Ser Ser Arg Met Lys Thr Phe Glu Glu Phe
1245 1250 1255
ccc atg acc cca acg acc tac aaa ggc tct gtg gac aac cag aca
3838Pro Met Thr Pro Thr Thr Tyr Lys Gly Ser Val Asp Asn Gln Thr
1260 1265 1270
gac agt ggg atg gtg ctg gcc tcg gag gag ttt gag cag ata gag
3883Asp Ser Gly Met Val Leu Ala Ser Glu Glu Phe Glu Gln Ile Glu
1275 1280 1285
agc agg cat aga caa gaa agc ggc ttc agg tagctgaagc agagagagag
3933Ser Arg His Arg Gln Glu Ser Gly Phe Arg
1290 1295
aaggcagcat acgtcagcat tttcttctct gcacttataa gaaagatcaa agactttaag
3993actttcgcta tttcttctac tgctatctac tacaaacttc aaagaggaac caggaggaca
4053agaggagcat gaaagtggac aaggagtgtg accactgaag caccacaggg aaggggttag
4113gcctccggat gactgcgggc aggcctggat aatatccagc ctcccacaag aagctggtgg
4173agcagagtgt tccctgactc ct
4195391298PRTHomo sapiens 39Met Gln Arg Gly Ala Ala Leu Cys Leu Arg Leu
Trp Leu Cys Leu Gly 1 5 10
15 Leu Leu Asp Gly Leu Val Ser Gly Tyr Ser Met Thr Pro Pro Thr Leu
20 25 30 Asn Ile
Thr Glu Glu Ser His Val Ile Asp Thr Gly Asp Ser Leu Ser 35
40 45 Ile Ser Cys Arg Gly Gln His
Pro Leu Glu Trp Ala Trp Pro Gly Ala 50 55
60 Gln Glu Ala Pro Ala Thr Gly Asp Lys Asp Ser Glu
Asp Thr Gly Val 65 70 75
80 Val Arg Asp Cys Glu Gly Thr Asp Ala Arg Pro Tyr Cys Lys Val Leu
85 90 95 Leu Leu His
Glu Val His Ala Asn Asp Thr Gly Ser Tyr Val Cys Tyr 100
105 110 Tyr Lys Tyr Ile Lys Ala Arg Ile
Glu Gly Thr Thr Ala Ala Ser Ser 115 120
125 Tyr Val Phe Val Arg Asp Phe Glu Gln Pro Phe Ile Asn
Lys Pro Asp 130 135 140
Thr Leu Leu Val Asn Arg Lys Asp Ala Met Trp Val Pro Cys Leu Val 145
150 155 160 Ser Ile Pro Gly
Leu Asn Val Thr Leu Arg Ser Gln Ser Ser Val Leu 165
170 175 Trp Pro Asp Gly Gln Glu Val Val Trp
Asp Asp Arg Arg Gly Met Leu 180 185
190 Val Ser Thr Pro Leu Leu His Asp Ala Leu Tyr Leu Gln Cys
Glu Thr 195 200 205
Thr Trp Gly Asp Gln Asp Phe Leu Ser Asn Pro Phe Leu Val His Ile 210
215 220 Thr Gly Asn Glu Leu
Tyr Asp Ile Gln Leu Leu Pro Arg Lys Ser Leu 225 230
235 240 Glu Leu Leu Val Gly Glu Lys Leu Val Leu
Asn Cys Thr Val Trp Ala 245 250
255 Glu Phe Asn Ser Gly Val Thr Phe Asp Trp Asp Tyr Pro Gly Lys
Gln 260 265 270 Ala
Glu Arg Gly Lys Trp Val Pro Glu Arg Arg Ser Gln Gln Thr His 275
280 285 Thr Glu Leu Ser Ser Ile
Leu Thr Ile His Asn Val Ser Gln His Asp 290 295
300 Leu Gly Ser Tyr Val Cys Lys Ala Asn Asn Gly
Ile Gln Arg Phe Arg 305 310 315
320 Glu Ser Thr Glu Val Ile Val His Glu Asn Pro Phe Ile Ser Val Glu
325 330 335 Trp Leu
Lys Gly Pro Ile Leu Glu Ala Thr Ala Gly Asp Glu Leu Val 340
345 350 Lys Leu Pro Val Lys Leu Ala
Ala Tyr Pro Pro Pro Glu Phe Gln Trp 355 360
365 Tyr Lys Asp Gly Lys Ala Leu Ser Gly Arg His Ser
Pro His Ala Leu 370 375 380
Val Leu Lys Glu Val Thr Glu Ala Ser Thr Gly Thr Tyr Thr Leu Ala 385
390 395 400 Leu Trp Asn
Ser Ala Ala Gly Leu Arg Arg Asn Ile Ser Leu Glu Leu 405
410 415 Val Val Asn Val Pro Pro Gln Ile
His Glu Lys Glu Ala Ser Ser Pro 420 425
430 Ser Ile Tyr Ser Arg His Ser Arg Gln Ala Leu Thr Cys
Thr Ala Tyr 435 440 445
Gly Val Pro Leu Pro Leu Ser Ile Gln Trp His Trp Arg Pro Trp Thr 450
455 460 Pro Cys Lys Met
Phe Ala Gln Arg Ser Leu Arg Arg Arg Gln Gln Gln 465 470
475 480 Asp Leu Met Pro Gln Cys Arg Asp Trp
Arg Ala Val Thr Thr Gln Asp 485 490
495 Ala Val Asn Pro Ile Glu Ser Leu Asp Thr Trp Thr Glu Phe
Val Glu 500 505 510
Gly Lys Asn Lys Thr Val Ser Lys Leu Val Ile Gln Asn Ala Asn Val
515 520 525 Ser Ala Met Tyr
Lys Cys Val Val Ser Asn Lys Val Gly Gln Asp Glu 530
535 540 Arg Leu Ile Tyr Phe Tyr Val Thr
Thr Ile Pro Asp Gly Phe Thr Ile 545 550
555 560 Glu Ser Lys Pro Ser Glu Glu Leu Leu Glu Gly Gln
Pro Val Leu Leu 565 570
575 Ser Cys Gln Ala Asp Ser Tyr Lys Tyr Glu His Leu Arg Trp Tyr Arg
580 585 590 Leu Asn Leu
Ser Thr Leu His Asp Ala His Gly Asn Pro Leu Leu Leu 595
600 605 Asp Cys Lys Asn Val His Leu Phe
Ala Thr Pro Leu Ala Ala Ser Leu 610 615
620 Glu Glu Val Ala Pro Gly Ala Arg His Ala Thr Leu Ser
Leu Ser Ile 625 630 635
640 Pro Arg Val Ala Pro Glu His Glu Gly His Tyr Val Cys Glu Val Gln
645 650 655 Asp Arg Arg Ser
His Asp Lys His Cys His Lys Lys Tyr Leu Ser Val 660
665 670 Gln Ala Leu Glu Ala Pro Arg Leu Thr
Gln Asn Leu Thr Asp Leu Leu 675 680
685 Val Asn Val Ser Asp Ser Leu Glu Met Gln Cys Leu Val Ala
Gly Ala 690 695 700
His Ala Pro Ser Ile Val Trp Tyr Lys Asp Glu Arg Leu Leu Glu Glu 705
710 715 720 Lys Ser Gly Val Asp
Leu Ala Asp Ser Asn Gln Lys Leu Ser Ile Gln 725
730 735 Arg Val Arg Glu Glu Asp Ala Gly Arg Tyr
Leu Cys Ser Val Cys Asn 740 745
750 Ala Lys Gly Cys Val Asn Ser Ser Ala Ser Val Ala Val Glu Gly
Ser 755 760 765 Glu
Asp Lys Gly Ser Met Glu Ile Val Ile Leu Val Gly Thr Gly Val 770
775 780 Ile Ala Val Phe Phe Trp
Val Leu Leu Leu Leu Ile Phe Cys Asn Met 785 790
795 800 Arg Arg Pro Ala His Ala Asp Ile Lys Thr Gly
Tyr Leu Ser Ile Ile 805 810
815 Met Asp Pro Gly Glu Val Pro Leu Glu Glu Gln Cys Glu Tyr Leu Ser
820 825 830 Tyr Asp
Ala Ser Gln Trp Glu Phe Pro Arg Glu Arg Leu His Leu Gly 835
840 845 Arg Val Leu Gly Tyr Gly Ala
Phe Gly Lys Val Val Glu Ala Ser Ala 850 855
860 Phe Gly Ile His Lys Gly Ser Ser Cys Asp Thr Val
Ala Val Lys Met 865 870 875
880 Leu Lys Glu Gly Ala Thr Ala Ser Glu His Arg Ala Leu Met Ser Glu
885 890 895 Leu Lys Ile
Leu Ile His Ile Gly Asn His Leu Asn Val Val Asn Leu 900
905 910 Leu Gly Ala Cys Thr Lys Pro Gln
Gly Pro Leu Met Val Ile Val Glu 915 920
925 Phe Cys Lys Tyr Gly Asn Leu Ser Asn Phe Leu Arg Ala
Lys Arg Asp 930 935 940
Ala Phe Ser Pro Cys Ala Glu Lys Ser Pro Glu Gln Arg Gly Arg Phe 945
950 955 960 Arg Ala Met Val
Glu Leu Ala Arg Leu Asp Arg Arg Arg Pro Gly Ser 965
970 975 Ser Asp Arg Val Leu Phe Ala Arg Phe
Ser Lys Thr Glu Gly Gly Ala 980 985
990 Arg Arg Ala Ser Pro Asp Gln Glu Ala Glu Asp Leu Trp
Leu Ser Pro 995 1000 1005
Leu Thr Met Glu Asp Leu Val Cys Tyr Ser Phe Gln Val Ala Arg
1010 1015 1020 Gly Met Glu
Phe Leu Ala Ser Arg Lys Cys Ile His Arg Asp Leu 1025
1030 1035 Ala Ala Arg Asn Ile Leu Leu Ser
Glu Ser Asp Val Val Lys Ile 1040 1045
1050 Cys Asp Phe Gly Leu Ala Arg Asp Ile Tyr Lys Asp Pro
Asp Tyr 1055 1060 1065
Val Arg Lys Gly Ser Ala Arg Leu Pro Leu Lys Trp Met Ala Pro 1070
1075 1080 Glu Ser Ile Phe Asp
Lys Val Tyr Thr Thr Gln Ser Asp Val Trp 1085 1090
1095 Ser Phe Gly Val Leu Leu Trp Glu Ile Phe
Ser Leu Gly Ala Ser 1100 1105 1110
Pro Tyr Pro Gly Val Gln Ile Asn Glu Glu Phe Cys Gln Arg Leu
1115 1120 1125 Arg Asp
Gly Thr Arg Met Arg Ala Pro Glu Leu Ala Thr Pro Ala 1130
1135 1140 Ile Arg Arg Ile Met Leu Asn
Cys Trp Ser Gly Asp Pro Lys Ala 1145 1150
1155 Arg Pro Ala Phe Ser Glu Leu Val Glu Ile Leu Gly
Asp Leu Leu 1160 1165 1170
Gln Gly Arg Gly Leu Gln Glu Glu Glu Glu Val Cys Met Ala Pro 1175
1180 1185 Arg Ser Ser Gln Ser
Ser Glu Glu Gly Ser Phe Ser Gln Val Ser 1190 1195
1200 Thr Met Ala Leu His Ile Ala Gln Ala Asp
Ala Glu Asp Ser Pro 1205 1210 1215
Pro Ser Leu Gln Arg His Ser Leu Ala Ala Arg Tyr Tyr Asn Trp
1220 1225 1230 Val Ser
Phe Pro Gly Cys Leu Ala Arg Gly Ala Glu Thr Arg Gly 1235
1240 1245 Ser Ser Arg Met Lys Thr Phe
Glu Glu Phe Pro Met Thr Pro Thr 1250 1255
1260 Thr Tyr Lys Gly Ser Val Asp Asn Gln Thr Asp Ser
Gly Met Val 1265 1270 1275
Leu Ala Ser Glu Glu Phe Glu Gln Ile Glu Ser Arg His Arg Gln 1280
1285 1290 Glu Ser Gly Phe Arg
1295 404795DNAHomo sapiensCDS(20)..(4111) 40ccacgcgcag
cggccggag atg cag cgg ggc gcc gcg ctg tgc ctg cga ctg 52
Met Gln Arg Gly Ala Ala Leu Cys Leu Arg Leu
1 5 10 tgg ctc tgc ctg
gga ctc ctg gac ggc ctg gtg agt ggc tac tcc atg 100Trp Leu Cys Leu
Gly Leu Leu Asp Gly Leu Val Ser Gly Tyr Ser Met 15
20 25 acc ccc ccg acc ttg
aac atc acg gag gag tca cac gtc atc gac acc 148Thr Pro Pro Thr Leu
Asn Ile Thr Glu Glu Ser His Val Ile Asp Thr 30
35 40 ggt gac agc ctg tcc atc
tcc tgc agg gga cag cac ccc ctc gag tgg 196Gly Asp Ser Leu Ser Ile
Ser Cys Arg Gly Gln His Pro Leu Glu Trp 45
50 55 gct tgg cca gga gct cag
gag gcg cca gcc acc gga gac aag gac agc 244Ala Trp Pro Gly Ala Gln
Glu Ala Pro Ala Thr Gly Asp Lys Asp Ser 60 65
70 75 gag gac acg ggg gtg gtg cga
gac tgc gag ggc aca gac gcc agg ccc 292Glu Asp Thr Gly Val Val Arg
Asp Cys Glu Gly Thr Asp Ala Arg Pro 80
85 90 tac tgc aag gtg ttg ctg ctg cac
gag gta cat gcc aac gac aca ggc 340Tyr Cys Lys Val Leu Leu Leu His
Glu Val His Ala Asn Asp Thr Gly 95
100 105 agc tac gtc tgc tac tac aag tac
atc aag gca cgc atc gag ggc acc 388Ser Tyr Val Cys Tyr Tyr Lys Tyr
Ile Lys Ala Arg Ile Glu Gly Thr 110 115
120 acg gcc gcc agc tcc tac gtg ttc gtg
aga gac ttt gag cag cca ttc 436Thr Ala Ala Ser Ser Tyr Val Phe Val
Arg Asp Phe Glu Gln Pro Phe 125 130
135 atc aac aag cct gac acg ctc ttg gtc aac
agg aag gac gcc atg tgg 484Ile Asn Lys Pro Asp Thr Leu Leu Val Asn
Arg Lys Asp Ala Met Trp 140 145
150 155 gtg ccc tgt ctg gtg tcc atc ccc ggc ctc
aat gtc acg ctg cgc tcg 532Val Pro Cys Leu Val Ser Ile Pro Gly Leu
Asn Val Thr Leu Arg Ser 160 165
170 caa agc tcg gtg ctg tgg cca gac ggg cag gag
gtg gtg tgg gat gac 580Gln Ser Ser Val Leu Trp Pro Asp Gly Gln Glu
Val Val Trp Asp Asp 175 180
185 cgg cgg ggc atg ctc gtg tcc acg cca ctg ctg cac
gat gcc ctg tac 628Arg Arg Gly Met Leu Val Ser Thr Pro Leu Leu His
Asp Ala Leu Tyr 190 195
200 ctg cag tgc gag acc acc tgg gga gac cag gac ttc
ctt tcc aac ccc 676Leu Gln Cys Glu Thr Thr Trp Gly Asp Gln Asp Phe
Leu Ser Asn Pro 205 210 215
ttc ctg gtg cac atc aca ggc aac gag ctc tat gac atc
cag ctg ttg 724Phe Leu Val His Ile Thr Gly Asn Glu Leu Tyr Asp Ile
Gln Leu Leu 220 225 230
235 ccc agg aag tcg ctg gag ctg ctg gta ggg gag aag ctg gtc
ctg aac 772Pro Arg Lys Ser Leu Glu Leu Leu Val Gly Glu Lys Leu Val
Leu Asn 240 245
250 tgc acc gtg tgg gct gag ttt aac tca ggt gtc acc ttt gac
tgg gac 820Cys Thr Val Trp Ala Glu Phe Asn Ser Gly Val Thr Phe Asp
Trp Asp 255 260 265
tac cca ggg aag cag gca gag cgg ggt aag tgg gtg ccc gag cga
cgc 868Tyr Pro Gly Lys Gln Ala Glu Arg Gly Lys Trp Val Pro Glu Arg
Arg 270 275 280
tcc cag cag acc cac aca gaa ctc tcc agc atc ctg acc atc cac aac
916Ser Gln Gln Thr His Thr Glu Leu Ser Ser Ile Leu Thr Ile His Asn
285 290 295
gtc agc cag cac gac ctg ggc tcg tat gtg tgc aag gcc aac aac ggc
964Val Ser Gln His Asp Leu Gly Ser Tyr Val Cys Lys Ala Asn Asn Gly
300 305 310 315
atc cag cga ttt cgg gag agc acc gag gtc att gtg cat gaa aat ccc
1012Ile Gln Arg Phe Arg Glu Ser Thr Glu Val Ile Val His Glu Asn Pro
320 325 330
ttc atc agc gtc gag tgg ctc aaa gga ccc atc ctg gag gcc acg gca
1060Phe Ile Ser Val Glu Trp Leu Lys Gly Pro Ile Leu Glu Ala Thr Ala
335 340 345
gga gac gag ctg gtg aag ctg ccc gtg aag ctg gca gcg tac ccc ccg
1108Gly Asp Glu Leu Val Lys Leu Pro Val Lys Leu Ala Ala Tyr Pro Pro
350 355 360
ccc gag ttc cag tgg tac aag gat gga aag gca ctg tcc ggg cgc cac
1156Pro Glu Phe Gln Trp Tyr Lys Asp Gly Lys Ala Leu Ser Gly Arg His
365 370 375
agt cca cat gcc ctg gtg ctc aag gag gtg aca gag gcc agc aca ggc
1204Ser Pro His Ala Leu Val Leu Lys Glu Val Thr Glu Ala Ser Thr Gly
380 385 390 395
acc tac acc ctc gcc ctg tgg aac tcc gct gct ggc ctg agg cgc aac
1252Thr Tyr Thr Leu Ala Leu Trp Asn Ser Ala Ala Gly Leu Arg Arg Asn
400 405 410
atc agc ctg gag ctg gtg gtg aat gtg ccc ccc cag ata cat gag aag
1300Ile Ser Leu Glu Leu Val Val Asn Val Pro Pro Gln Ile His Glu Lys
415 420 425
gag gcc tcc tcc ccc agc atc tac tcg cgt cac agc cgc cag gcc ctc
1348Glu Ala Ser Ser Pro Ser Ile Tyr Ser Arg His Ser Arg Gln Ala Leu
430 435 440
acc tgc acg gcc tac ggg gtg ccc ctg cct ctc agc atc cag tgg cac
1396Thr Cys Thr Ala Tyr Gly Val Pro Leu Pro Leu Ser Ile Gln Trp His
445 450 455
tgg cgg ccc tgg aca ccc tgc aag atg ttt gcc cag cgt agt ctc cgg
1444Trp Arg Pro Trp Thr Pro Cys Lys Met Phe Ala Gln Arg Ser Leu Arg
460 465 470 475
cgg cgg cag cag caa gac ctc atg cca cag tgc cgt gac tgg agg gcg
1492Arg Arg Gln Gln Gln Asp Leu Met Pro Gln Cys Arg Asp Trp Arg Ala
480 485 490
gtg acc acg cag gat gcc gtg aac ccc atc gag agc ctg gac acc tgg
1540Val Thr Thr Gln Asp Ala Val Asn Pro Ile Glu Ser Leu Asp Thr Trp
495 500 505
acc gag ttt gtg gag gga aag aat aag act gtg agc aag ctg gtg atc
1588Thr Glu Phe Val Glu Gly Lys Asn Lys Thr Val Ser Lys Leu Val Ile
510 515 520
cag aat gcc aac gtg tct gcc atg tac aag tgt gtg gtc tcc aac aag
1636Gln Asn Ala Asn Val Ser Ala Met Tyr Lys Cys Val Val Ser Asn Lys
525 530 535
gtg ggc cag gat gag cgg ctc atc tac ttc tat gtg acc acc atc ccc
1684Val Gly Gln Asp Glu Arg Leu Ile Tyr Phe Tyr Val Thr Thr Ile Pro
540 545 550 555
gac ggc ttc acc atc gaa tcc aag cca tcc gag gag cta cta gag ggc
1732Asp Gly Phe Thr Ile Glu Ser Lys Pro Ser Glu Glu Leu Leu Glu Gly
560 565 570
cag ccg gtg ctc ctg agc tgc caa gcc gac agc tac aag tac gag cat
1780Gln Pro Val Leu Leu Ser Cys Gln Ala Asp Ser Tyr Lys Tyr Glu His
575 580 585
ctg cgc tgg tac cgc ctc aac ctg tcc acg ctg cac gat gcg cac ggg
1828Leu Arg Trp Tyr Arg Leu Asn Leu Ser Thr Leu His Asp Ala His Gly
590 595 600
aac ccg ctt ctg ctc gac tgc aag aac gtg cat ctg ttc gcc acc cct
1876Asn Pro Leu Leu Leu Asp Cys Lys Asn Val His Leu Phe Ala Thr Pro
605 610 615
ctg gcc gcc agc ctg gag gag gtg gca cct ggg gcg cgc cac gcc acg
1924Leu Ala Ala Ser Leu Glu Glu Val Ala Pro Gly Ala Arg His Ala Thr
620 625 630 635
ctc agc ctg agt atc ccc cgc gtc gcg ccc gag cac gag ggc cac tat
1972Leu Ser Leu Ser Ile Pro Arg Val Ala Pro Glu His Glu Gly His Tyr
640 645 650
gtg tgc gaa gtg caa gac cgg cgc agc cat gac aag cac tgc cac aag
2020Val Cys Glu Val Gln Asp Arg Arg Ser His Asp Lys His Cys His Lys
655 660 665
aag tac ctg tcg gtg cag gcc ctg gaa gcc cct cgg ctc acg cag aac
2068Lys Tyr Leu Ser Val Gln Ala Leu Glu Ala Pro Arg Leu Thr Gln Asn
670 675 680
ttg acc gac ctc ctg gtg aac gtg agc gac tcg ctg gag atg cag tgc
2116Leu Thr Asp Leu Leu Val Asn Val Ser Asp Ser Leu Glu Met Gln Cys
685 690 695
ttg gtg gcc gga gcg cac gcg ccc agc atc gtg tgg tac aaa gac gag
2164Leu Val Ala Gly Ala His Ala Pro Ser Ile Val Trp Tyr Lys Asp Glu
700 705 710 715
agg ctg ctg gag gaa aag tct gga gtc gac ttg gcg gac tcc aac cag
2212Arg Leu Leu Glu Glu Lys Ser Gly Val Asp Leu Ala Asp Ser Asn Gln
720 725 730
aag ctg agc atc cag cgc gtg cgc gag gag gat gcg gga cgc tat ctg
2260Lys Leu Ser Ile Gln Arg Val Arg Glu Glu Asp Ala Gly Arg Tyr Leu
735 740 745
tgc agc gtg tgc aac gcc aag ggc tgc gtc aac tcc tcc gcc agc gtg
2308Cys Ser Val Cys Asn Ala Lys Gly Cys Val Asn Ser Ser Ala Ser Val
750 755 760
gcc gtg gaa ggc tcc gag gat aag ggc agc atg gag atc gtg atc ctt
2356Ala Val Glu Gly Ser Glu Asp Lys Gly Ser Met Glu Ile Val Ile Leu
765 770 775
gtc ggt acc ggc gtc atc gct gtc ttc ttc tgg gtc ctc ctc ctc ctc
2404Val Gly Thr Gly Val Ile Ala Val Phe Phe Trp Val Leu Leu Leu Leu
780 785 790 795
atc ttc tgt aac atg agg agg ccg gcc cac gca gac atc aag acg ggc
2452Ile Phe Cys Asn Met Arg Arg Pro Ala His Ala Asp Ile Lys Thr Gly
800 805 810
tac ctg tcc atc atc atg gac ccc ggg gag gtg cct ctg gag gag caa
2500Tyr Leu Ser Ile Ile Met Asp Pro Gly Glu Val Pro Leu Glu Glu Gln
815 820 825
tgc gaa tac ctg tcc tac gat gcc agc cag tgg gaa ttc ccc cga gag
2548Cys Glu Tyr Leu Ser Tyr Asp Ala Ser Gln Trp Glu Phe Pro Arg Glu
830 835 840
cgg ctg cac ctg ggg aga gtg ctc ggc tac ggc gcc ttc ggg aag gtg
2596Arg Leu His Leu Gly Arg Val Leu Gly Tyr Gly Ala Phe Gly Lys Val
845 850 855
gtg gaa gcc tcc gct ttc ggc atc cac aag ggc agc agc tgt gac acc
2644Val Glu Ala Ser Ala Phe Gly Ile His Lys Gly Ser Ser Cys Asp Thr
860 865 870 875
gtg gcc gtg aaa atg ctg aaa gag ggc gcc acg gcc agc gag cac cgc
2692Val Ala Val Lys Met Leu Lys Glu Gly Ala Thr Ala Ser Glu His Arg
880 885 890
gcg ctg atg tcg gag ctc aag atc ctc att cac atc ggc aac cac ctc
2740Ala Leu Met Ser Glu Leu Lys Ile Leu Ile His Ile Gly Asn His Leu
895 900 905
aac gtg gtc aac ctc ctc ggg gcg tgc acc aag ccg cag ggc ccc ctc
2788Asn Val Val Asn Leu Leu Gly Ala Cys Thr Lys Pro Gln Gly Pro Leu
910 915 920
atg gtg atc gtg gag ttc tgc aag tac ggc aac ctc tcc aac ttc ctg
2836Met Val Ile Val Glu Phe Cys Lys Tyr Gly Asn Leu Ser Asn Phe Leu
925 930 935
cgc gcc aag cgg gac gcc ttc agc ccc tgc gcg gag aag tct ccc gag
2884Arg Ala Lys Arg Asp Ala Phe Ser Pro Cys Ala Glu Lys Ser Pro Glu
940 945 950 955
cag cgc gga cgc ttc cgc gcc atg gtg gag ctc gcc agg ctg gat cgg
2932Gln Arg Gly Arg Phe Arg Ala Met Val Glu Leu Ala Arg Leu Asp Arg
960 965 970
agg cgg ccg ggg agc agc gac agg gtc ctc ttc gcg cgg ttc tcg aag
2980Arg Arg Pro Gly Ser Ser Asp Arg Val Leu Phe Ala Arg Phe Ser Lys
975 980 985
acc gag ggc gga gcg agg cgg gct tct cca gac caa gaa gct gag gac
3028Thr Glu Gly Gly Ala Arg Arg Ala Ser Pro Asp Gln Glu Ala Glu Asp
990 995 1000
ctg tgg ctg agc ccg ctg acc atg gaa gat ctt gtc tgc tac agc
3073Leu Trp Leu Ser Pro Leu Thr Met Glu Asp Leu Val Cys Tyr Ser
1005 1010 1015
ttc cag gtg gcc aga ggg atg gag ttc ctg gct tcc cga aag tgc
3118Phe Gln Val Ala Arg Gly Met Glu Phe Leu Ala Ser Arg Lys Cys
1020 1025 1030
atc cac aga gac ctg gct gct cgg aac att ctg ctg tcg gaa agc
3163Ile His Arg Asp Leu Ala Ala Arg Asn Ile Leu Leu Ser Glu Ser
1035 1040 1045
gac gtg gtg aag atc tgt gac ttt ggc ctt gcc cgg gac atc tac
3208Asp Val Val Lys Ile Cys Asp Phe Gly Leu Ala Arg Asp Ile Tyr
1050 1055 1060
aaa gac cct gac tac gtc cgc aag ggc agt gcc cgg ctg ccc ctg
3253Lys Asp Pro Asp Tyr Val Arg Lys Gly Ser Ala Arg Leu Pro Leu
1065 1070 1075
aag tgg atg gcc cct gaa agc atc ttc gac aag gtg tac acc acg
3298Lys Trp Met Ala Pro Glu Ser Ile Phe Asp Lys Val Tyr Thr Thr
1080 1085 1090
cag agt gac gtg tgg tcc ttt ggg gtg ctt ctc tgg gag atc ttc
3343Gln Ser Asp Val Trp Ser Phe Gly Val Leu Leu Trp Glu Ile Phe
1095 1100 1105
tct ctg ggg gcc tcc ccg tac cct ggg gtg cag atc aat gag gag
3388Ser Leu Gly Ala Ser Pro Tyr Pro Gly Val Gln Ile Asn Glu Glu
1110 1115 1120
ttc tgc cag cgg ctg aga gac ggc aca agg atg agg gcc ccg gag
3433Phe Cys Gln Arg Leu Arg Asp Gly Thr Arg Met Arg Ala Pro Glu
1125 1130 1135
ctg gcc act ccc gcc ata cgc cgc atc atg ctg aac tgc tgg tcc
3478Leu Ala Thr Pro Ala Ile Arg Arg Ile Met Leu Asn Cys Trp Ser
1140 1145 1150
gga gac ccc aag gcg aga cct gca ttc tcg gag ctg gtg gag atc
3523Gly Asp Pro Lys Ala Arg Pro Ala Phe Ser Glu Leu Val Glu Ile
1155 1160 1165
ctg ggg gac ctg ctc cag ggc agg ggc ctg caa gag gaa gag gag
3568Leu Gly Asp Leu Leu Gln Gly Arg Gly Leu Gln Glu Glu Glu Glu
1170 1175 1180
gtc tgc atg gcc ccg cgc agc tct cag agc tca gaa gag ggc agc
3613Val Cys Met Ala Pro Arg Ser Ser Gln Ser Ser Glu Glu Gly Ser
1185 1190 1195
ttc tcg cag gtg tcc acc atg gcc cta cac atc gcc cag gct gac
3658Phe Ser Gln Val Ser Thr Met Ala Leu His Ile Ala Gln Ala Asp
1200 1205 1210
gct gag gac agc ccg cca agc ctg cag cgc cac agc ctg gcc gcc
3703Ala Glu Asp Ser Pro Pro Ser Leu Gln Arg His Ser Leu Ala Ala
1215 1220 1225
agg tat tac aac tgg gtg tcc ttt ccc ggg tgc ctg gcc aga ggg
3748Arg Tyr Tyr Asn Trp Val Ser Phe Pro Gly Cys Leu Ala Arg Gly
1230 1235 1240
gct gag acc cgt ggt tcc tcc agg atg aag aca ttt gag gaa ttc
3793Ala Glu Thr Arg Gly Ser Ser Arg Met Lys Thr Phe Glu Glu Phe
1245 1250 1255
ccc atg acc cca acg acc tac aaa ggc tct gtg gac aac cag aca
3838Pro Met Thr Pro Thr Thr Tyr Lys Gly Ser Val Asp Asn Gln Thr
1260 1265 1270
gac agt ggg atg gtg ctg gcc tcg gag gag ttt gag cag ata gag
3883Asp Ser Gly Met Val Leu Ala Ser Glu Glu Phe Glu Gln Ile Glu
1275 1280 1285
agc agg cat aga caa gaa agc ggc ttc agc tgt aaa gga cct ggc
3928Ser Arg His Arg Gln Glu Ser Gly Phe Ser Cys Lys Gly Pro Gly
1290 1295 1300
cag aat gtg gct gtg acc agg gca cac cct gac tcc caa ggg agg
3973Gln Asn Val Ala Val Thr Arg Ala His Pro Asp Ser Gln Gly Arg
1305 1310 1315
cgg cgg cgg cct gag cgg ggg gcc cga gga ggc cag gtg ttt tac
4018Arg Arg Arg Pro Glu Arg Gly Ala Arg Gly Gly Gln Val Phe Tyr
1320 1325 1330
aac agc gag tat ggg gag ctg tcg gag cca agc gag gag gac cac
4063Asn Ser Glu Tyr Gly Glu Leu Ser Glu Pro Ser Glu Glu Asp His
1335 1340 1345
tgc tcc ccg tct gcc cgc gtg act ttc ttc aca gac aac agc tac
4108Cys Ser Pro Ser Ala Arg Val Thr Phe Phe Thr Asp Asn Ser Tyr
1350 1355 1360
taa gcagcatcgg acaagacccc cagcacttgg gggttcaggc ccggcagggc
4161gggcagaggg ctggaggccc aggctgggaa ctcatctggt tgaactctgg tggcacagga
4221gtgtcctctt ccctctctgc agacttccca gctaggaaga gcaggactcc aggcccaagg
4281ctcccggaat tccgtcacca cgactggcca gggcacgctc cagctgcccc ggcccctccc
4341cctgagattc agatgtcatt tagttcagca tccgcaggtg ctggtcccgg ggccagcact
4401tccatgggaa tgtctctttg gcgacctcct ttcatcacac tgggtggtgg cctggtccct
4461gttttcccac gaggaatctg tgggtctggg agtcacacag tgttggaggt taaggcatac
4521gagagcagag gtctcccaaa cgccctttcc tcctcaggca cacagctact ctccccacga
4581gggctggctg gcctcaccca cccctgcaca gttgaaggga ggggctgtgt ttccatctca
4641aagaaggcat ttgcagggtc ctcttctggg cctgaccaaa cagccaacta gcccctgggg
4701tggccaccag tatgacagta ttatacgctg gcaacacaga ggcagcccgc acacctgcgc
4761ctgggtgttg agagccatcc tgcaagtctt tttc
4795411363PRTHomo sapiens 41Met Gln Arg Gly Ala Ala Leu Cys Leu Arg Leu
Trp Leu Cys Leu Gly 1 5 10
15 Leu Leu Asp Gly Leu Val Ser Gly Tyr Ser Met Thr Pro Pro Thr Leu
20 25 30 Asn Ile
Thr Glu Glu Ser His Val Ile Asp Thr Gly Asp Ser Leu Ser 35
40 45 Ile Ser Cys Arg Gly Gln His
Pro Leu Glu Trp Ala Trp Pro Gly Ala 50 55
60 Gln Glu Ala Pro Ala Thr Gly Asp Lys Asp Ser Glu
Asp Thr Gly Val 65 70 75
80 Val Arg Asp Cys Glu Gly Thr Asp Ala Arg Pro Tyr Cys Lys Val Leu
85 90 95 Leu Leu His
Glu Val His Ala Asn Asp Thr Gly Ser Tyr Val Cys Tyr 100
105 110 Tyr Lys Tyr Ile Lys Ala Arg Ile
Glu Gly Thr Thr Ala Ala Ser Ser 115 120
125 Tyr Val Phe Val Arg Asp Phe Glu Gln Pro Phe Ile Asn
Lys Pro Asp 130 135 140
Thr Leu Leu Val Asn Arg Lys Asp Ala Met Trp Val Pro Cys Leu Val 145
150 155 160 Ser Ile Pro Gly
Leu Asn Val Thr Leu Arg Ser Gln Ser Ser Val Leu 165
170 175 Trp Pro Asp Gly Gln Glu Val Val Trp
Asp Asp Arg Arg Gly Met Leu 180 185
190 Val Ser Thr Pro Leu Leu His Asp Ala Leu Tyr Leu Gln Cys
Glu Thr 195 200 205
Thr Trp Gly Asp Gln Asp Phe Leu Ser Asn Pro Phe Leu Val His Ile 210
215 220 Thr Gly Asn Glu Leu
Tyr Asp Ile Gln Leu Leu Pro Arg Lys Ser Leu 225 230
235 240 Glu Leu Leu Val Gly Glu Lys Leu Val Leu
Asn Cys Thr Val Trp Ala 245 250
255 Glu Phe Asn Ser Gly Val Thr Phe Asp Trp Asp Tyr Pro Gly Lys
Gln 260 265 270 Ala
Glu Arg Gly Lys Trp Val Pro Glu Arg Arg Ser Gln Gln Thr His 275
280 285 Thr Glu Leu Ser Ser Ile
Leu Thr Ile His Asn Val Ser Gln His Asp 290 295
300 Leu Gly Ser Tyr Val Cys Lys Ala Asn Asn Gly
Ile Gln Arg Phe Arg 305 310 315
320 Glu Ser Thr Glu Val Ile Val His Glu Asn Pro Phe Ile Ser Val Glu
325 330 335 Trp Leu
Lys Gly Pro Ile Leu Glu Ala Thr Ala Gly Asp Glu Leu Val 340
345 350 Lys Leu Pro Val Lys Leu Ala
Ala Tyr Pro Pro Pro Glu Phe Gln Trp 355 360
365 Tyr Lys Asp Gly Lys Ala Leu Ser Gly Arg His Ser
Pro His Ala Leu 370 375 380
Val Leu Lys Glu Val Thr Glu Ala Ser Thr Gly Thr Tyr Thr Leu Ala 385
390 395 400 Leu Trp Asn
Ser Ala Ala Gly Leu Arg Arg Asn Ile Ser Leu Glu Leu 405
410 415 Val Val Asn Val Pro Pro Gln Ile
His Glu Lys Glu Ala Ser Ser Pro 420 425
430 Ser Ile Tyr Ser Arg His Ser Arg Gln Ala Leu Thr Cys
Thr Ala Tyr 435 440 445
Gly Val Pro Leu Pro Leu Ser Ile Gln Trp His Trp Arg Pro Trp Thr 450
455 460 Pro Cys Lys Met
Phe Ala Gln Arg Ser Leu Arg Arg Arg Gln Gln Gln 465 470
475 480 Asp Leu Met Pro Gln Cys Arg Asp Trp
Arg Ala Val Thr Thr Gln Asp 485 490
495 Ala Val Asn Pro Ile Glu Ser Leu Asp Thr Trp Thr Glu Phe
Val Glu 500 505 510
Gly Lys Asn Lys Thr Val Ser Lys Leu Val Ile Gln Asn Ala Asn Val
515 520 525 Ser Ala Met Tyr
Lys Cys Val Val Ser Asn Lys Val Gly Gln Asp Glu 530
535 540 Arg Leu Ile Tyr Phe Tyr Val Thr
Thr Ile Pro Asp Gly Phe Thr Ile 545 550
555 560 Glu Ser Lys Pro Ser Glu Glu Leu Leu Glu Gly Gln
Pro Val Leu Leu 565 570
575 Ser Cys Gln Ala Asp Ser Tyr Lys Tyr Glu His Leu Arg Trp Tyr Arg
580 585 590 Leu Asn Leu
Ser Thr Leu His Asp Ala His Gly Asn Pro Leu Leu Leu 595
600 605 Asp Cys Lys Asn Val His Leu Phe
Ala Thr Pro Leu Ala Ala Ser Leu 610 615
620 Glu Glu Val Ala Pro Gly Ala Arg His Ala Thr Leu Ser
Leu Ser Ile 625 630 635
640 Pro Arg Val Ala Pro Glu His Glu Gly His Tyr Val Cys Glu Val Gln
645 650 655 Asp Arg Arg Ser
His Asp Lys His Cys His Lys Lys Tyr Leu Ser Val 660
665 670 Gln Ala Leu Glu Ala Pro Arg Leu Thr
Gln Asn Leu Thr Asp Leu Leu 675 680
685 Val Asn Val Ser Asp Ser Leu Glu Met Gln Cys Leu Val Ala
Gly Ala 690 695 700
His Ala Pro Ser Ile Val Trp Tyr Lys Asp Glu Arg Leu Leu Glu Glu 705
710 715 720 Lys Ser Gly Val Asp
Leu Ala Asp Ser Asn Gln Lys Leu Ser Ile Gln 725
730 735 Arg Val Arg Glu Glu Asp Ala Gly Arg Tyr
Leu Cys Ser Val Cys Asn 740 745
750 Ala Lys Gly Cys Val Asn Ser Ser Ala Ser Val Ala Val Glu Gly
Ser 755 760 765 Glu
Asp Lys Gly Ser Met Glu Ile Val Ile Leu Val Gly Thr Gly Val 770
775 780 Ile Ala Val Phe Phe Trp
Val Leu Leu Leu Leu Ile Phe Cys Asn Met 785 790
795 800 Arg Arg Pro Ala His Ala Asp Ile Lys Thr Gly
Tyr Leu Ser Ile Ile 805 810
815 Met Asp Pro Gly Glu Val Pro Leu Glu Glu Gln Cys Glu Tyr Leu Ser
820 825 830 Tyr Asp
Ala Ser Gln Trp Glu Phe Pro Arg Glu Arg Leu His Leu Gly 835
840 845 Arg Val Leu Gly Tyr Gly Ala
Phe Gly Lys Val Val Glu Ala Ser Ala 850 855
860 Phe Gly Ile His Lys Gly Ser Ser Cys Asp Thr Val
Ala Val Lys Met 865 870 875
880 Leu Lys Glu Gly Ala Thr Ala Ser Glu His Arg Ala Leu Met Ser Glu
885 890 895 Leu Lys Ile
Leu Ile His Ile Gly Asn His Leu Asn Val Val Asn Leu 900
905 910 Leu Gly Ala Cys Thr Lys Pro Gln
Gly Pro Leu Met Val Ile Val Glu 915 920
925 Phe Cys Lys Tyr Gly Asn Leu Ser Asn Phe Leu Arg Ala
Lys Arg Asp 930 935 940
Ala Phe Ser Pro Cys Ala Glu Lys Ser Pro Glu Gln Arg Gly Arg Phe 945
950 955 960 Arg Ala Met Val
Glu Leu Ala Arg Leu Asp Arg Arg Arg Pro Gly Ser 965
970 975 Ser Asp Arg Val Leu Phe Ala Arg Phe
Ser Lys Thr Glu Gly Gly Ala 980 985
990 Arg Arg Ala Ser Pro Asp Gln Glu Ala Glu Asp Leu Trp
Leu Ser Pro 995 1000 1005
Leu Thr Met Glu Asp Leu Val Cys Tyr Ser Phe Gln Val Ala Arg
1010 1015 1020 Gly Met Glu
Phe Leu Ala Ser Arg Lys Cys Ile His Arg Asp Leu 1025
1030 1035 Ala Ala Arg Asn Ile Leu Leu Ser
Glu Ser Asp Val Val Lys Ile 1040 1045
1050 Cys Asp Phe Gly Leu Ala Arg Asp Ile Tyr Lys Asp Pro
Asp Tyr 1055 1060 1065
Val Arg Lys Gly Ser Ala Arg Leu Pro Leu Lys Trp Met Ala Pro 1070
1075 1080 Glu Ser Ile Phe Asp
Lys Val Tyr Thr Thr Gln Ser Asp Val Trp 1085 1090
1095 Ser Phe Gly Val Leu Leu Trp Glu Ile Phe
Ser Leu Gly Ala Ser 1100 1105 1110
Pro Tyr Pro Gly Val Gln Ile Asn Glu Glu Phe Cys Gln Arg Leu
1115 1120 1125 Arg Asp
Gly Thr Arg Met Arg Ala Pro Glu Leu Ala Thr Pro Ala 1130
1135 1140 Ile Arg Arg Ile Met Leu Asn
Cys Trp Ser Gly Asp Pro Lys Ala 1145 1150
1155 Arg Pro Ala Phe Ser Glu Leu Val Glu Ile Leu Gly
Asp Leu Leu 1160 1165 1170
Gln Gly Arg Gly Leu Gln Glu Glu Glu Glu Val Cys Met Ala Pro 1175
1180 1185 Arg Ser Ser Gln Ser
Ser Glu Glu Gly Ser Phe Ser Gln Val Ser 1190 1195
1200 Thr Met Ala Leu His Ile Ala Gln Ala Asp
Ala Glu Asp Ser Pro 1205 1210 1215
Pro Ser Leu Gln Arg His Ser Leu Ala Ala Arg Tyr Tyr Asn Trp
1220 1225 1230 Val Ser
Phe Pro Gly Cys Leu Ala Arg Gly Ala Glu Thr Arg Gly 1235
1240 1245 Ser Ser Arg Met Lys Thr Phe
Glu Glu Phe Pro Met Thr Pro Thr 1250 1255
1260 Thr Tyr Lys Gly Ser Val Asp Asn Gln Thr Asp Ser
Gly Met Val 1265 1270 1275
Leu Ala Ser Glu Glu Phe Glu Gln Ile Glu Ser Arg His Arg Gln 1280
1285 1290 Glu Ser Gly Phe Ser
Cys Lys Gly Pro Gly Gln Asn Val Ala Val 1295 1300
1305 Thr Arg Ala His Pro Asp Ser Gln Gly Arg
Arg Arg Arg Pro Glu 1310 1315 1320
Arg Gly Ala Arg Gly Gly Gln Val Phe Tyr Asn Ser Glu Tyr Gly
1325 1330 1335 Glu Leu
Ser Glu Pro Ser Glu Glu Asp His Cys Ser Pro Ser Ala 1340
1345 1350 Arg Val Thr Phe Phe Thr Asp
Asn Ser Tyr 1355 1360 4210PRTArtificial
SequenceSynthetic peptide 42Cys Gly Tyr Trp Leu Thr Ile Trp Gly Cys 1
5 10 4313PRTArtificial SequenceSynthetic
peptide 43Cys Ala Ser Glu Leu Gly Lys Ser Thr Asn Thr Phe Cys 1
5 10 448PRTArtificial
SequenceSynthetic peptide 44Cys Asn Glu Glu Ser Leu Ile Cys 1
5 4511PRTArtificial SequenceSynthetic peptide 45Cys Ile
Ser Val Pro Leu Thr Ser Val Pro Cys 1 5
10 46132PRTArtificial SequenceSynthetic peptide 46Met Lys Leu Pro
Val Arg Leu Leu Val Leu Met Phe Trp Ile Pro Ala 1 5
10 15 Ser Ser Ser Asp Phe Val Met Thr Gln
Thr Pro Leu Ser Leu Pro Val 20 25
30 Ser Leu Gly Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln
Ser Leu 35 40 45
Val His Ser Asn Gly Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro 50
55 60 Gly Gln Ser Pro Lys
Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser 65 70
75 80 Gly Val Pro Asp Arg Phe Ser Gly Ser Gly
Ser Gly Thr Asp Phe Thr 85 90
95 Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe
Cys 100 105 110 Ser
Gln Ser Thr His Val Pro Arg Thr Phe Gly Gly Gly Thr Lys Leu 115
120 125 Glu Ile Lys Arg 130
47137PRTArtificial SequenceSynthetic peptide 47Met Gly Trp Ser
Gly Val Phe Leu Phe Leu Leu Ser Gly Ser Thr Gly 1 5
10 15 Val His Ser Glu Ile Gln Leu Gln Gln
Ser Gly Pro Asp Leu Val Lys 20 25
30 Pro Gly Ala Ser Val Lys Val Ser Cys Arg Ala Ser Gly Tyr
Ser Phe 35 40 45
Thr Gly Tyr Asn Met Tyr Trp Val Lys Gln Ser His Gly Lys Ser Leu 50
55 60 Glu Trp Ile Gly Tyr
Ile Asp Pro Tyr Asn Gly Asp Thr Thr Tyr Asn 65 70
75 80 Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr
Val Asp Lys Ser Ser Ser 85 90
95 Thr Ala Phe Met His Leu Asn Ser Leu Thr Ser Glu Asp Ser Ala
Val 100 105 110 Tyr
Tyr Cys Ala Arg Thr Ser Tyr Tyr Gly Gly Met Asp Tyr Trp Gly 115
120 125 Gln Gly Thr Ser Val Thr
Val Ser Ser 130 135 4816PRTArtificial
SequenceSynthetic peptide 48Arg Ser Ser Gln Ser Leu Val His Ser Asn Gly
Asn Thr Tyr Leu His 1 5 10
15 497PRTArtificial SequenceSynthetic peptide 49Lys Val Ser Asn
Arg Phe Ser 1 5 509PRTArtificial
SequenceSynthetic peptide 50Ser Gln Ser Thr His Val Pro Arg Thr 1
5 5110PRTArtificial SequenceSynthetic peptide
51Gly Tyr Ser Phe Thr Gly Tyr Asn Met Tyr 1 5
10 5217PRTArtificial SequenceSynthetic peptide 52Tyr Ile Asp Pro Tyr
Asn Gly Asp Thr Thr Tyr Asn Gln Lys Phe Lys 1 5
10 15 Gly 539PRTArtificial SequenceSynthetic
peptide 53Thr Ser Tyr Tyr Gly Gly Met Asp Tyr 1 5
User Contributions:
Comment about this patent or add new information about this topic: